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 ABSTRACT 
 
Cryptosporidiosis is a common diarrheal disease caused by intestinal infection 
with the apicomplexan parasite Cryptosporidium, in humans usually either with C. 
hominis or C. parvum.  Unfortunately, given a large burden of disease in children and 
immunocompromised people like AIDS patients, the only currently approved treatment, 
nitazoxanide, is unreliable for these patient populations. To address the urgent need for 
new drugs for the most vulnerable populations, large phenotypic screening efforts have 
been established to identify anti-Cryptosporidium growth inhibitors in vitro (hits).  
However, in the absence of a gold standard drug, the in vitro and in vivo characteristics 
that should be used to prioritize screening hits are not known.  This thesis is focused on 
identifying promising anti-Cryptosporidium hits and drug leads, and using them to 
establish validated methods to guide hit-to-lead studies for anti-Cryptosporidium drug 
development. 
 
A re-analysis of our phenotypic screen of the Medicines for Malaria Venture 
Open Access Malaria Box identified a promising C. parvum growth inhibitor, 
MMV665917.  It had similar in vitro activity against C. hominis, C. parvum Iowa, and 
C. parvum field strains, and it was amenable to preliminary structural activity 
relationship studies using commercially available variants, with one variant 
demonstrating nanomolar potency.  Furthermore, MMV665917 was effective in vivo in 
an acute interferon-γ mouse model of cryptosporidiosis; and it appeared to cure an 
established infection in the chronic NOD SCID gamma (NSG) mouse model, unlike 
nitazoxanide, paromomycin, and clofazimine.  We hypothesized that anti-
Cryptosporidium activity in the highly immunocompromised chronic NSG mouse 
model might relate to compounds being capable of killing and eliminating parasites 
(cidal), rather than only preventing growth (static).  To test this, we developed a novel 
in vitro parasite persistence assay that showed that MMV665917 was potentially cidal, 
whereas nitazoxanide, paromomycin and clofazimine appeared static.  This 
pharmacodynamic assay also provided the concentration of compound required to 
maximize rate of parasite elimination, which could help design in vivo experiments.   
 
To further characterize compounds based on mechanism of action, we 
developed a range of in vitro medium-throughput life-stage assays.  To validate and 
gain value from the assays, a “learner set” of compounds from our in-house screens and 
collaborations were tested in all of the in vitro assays and in the in vivo NSG mouse 
model.  Using these assays, it was possible to group molecules based on chemical 
class/mechanism of action.  Because compounds from distinct groups showed activity 
in the NSG mouse model, these methods could be used to obtain a diverse set of early-
stage Cryptosporidium inhibitors for prioritization.  Furthermore, compounds that 
appeared static in the in vitro parasite persistence assay did not have activity in the 
NSG mouse model.  In summary, we report the identification and development of a 
highly promising initial lead, MMV665917, and report a range of in vitro assays that 
can be used to prioritize anti-Cryptosporidium hits and leads.
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 CHAPTER 1: COMPREHENSIVE LITERATURE REVIEW 
1.1.  Introduction 
The goal of this thesis is to identify and develop anti-Cryptosporidium 
compounds, with a major focus to develop relatively inexpensive in vitro assays to 
rationally aide the initial stages of Cryptosporidium drug discovery and development.  
This Chapter provides a background about the medical importance of the disease, 
followed by early stage drug development strategies used for other neglected tropical 
diseases, and how we have adapted them in part for anti-Cryptosporidium drug 
development. 
Cryptosporidiosis is a water-borne diarrheal disease that is caused by eukaryotic 
Cryptosporidium parasites, of which there are many species.  Cryptosporidium belongs 
to the phylum Apicomplexa, which also includes other well-studied and medically 
important parasites like Toxoplasma and Plasmodium species (Perkins, Barta, Clopton, 
Peirce, & Upton, 2000). 
 
1.2.  Historical Perspective   
Although first reported in the peptic glands of the common mouse by Ernest 
Edward Tyzzer in 1907 (Tyzzer, 1907, 1910), Cryptosporidium was reported to cause 
disease in animals only in 1955 after the identification of C. meleagridis in turkeys 
(Slavin, 1955).  Medical and agricultural interest in Cryptosporidium grew after reports 
of its ability to cause disease in cattle in the early 1970s (Meuten, Van Kruiningen, & 
Lein, 1974; Panciera, Thomassen, & Garner, 1971).  Soon after, two separate human 
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reports of watery diarrhea caused by intestinal Cryptosporidium infection in a 3-year-
old child and a 39-year-old immunosuppressed patient with exposure to cattle, emerged 
in 1976 (Meisel, Perera, Meligro, & Rubin, 1976; Nime, Burek, Page, Holscher, & 
Yardley, 1976).  In 1979 two more immunosuppressed human cryptosporidiosis cases 
were published, wherein the patients did not live on a farm and the source of infection 
was unclear (Lasser, Lewin, & Ryning, 1979; Weisburger et al., 1979).  These reports 
suggested a possible link between immunosuppression and cryptosporidiosis.  During 
the same period, several Cryptosporidium species were identified in animals ranging 
from snakes and rabbits to sheep and monkeys.  However, the role of Cryptosporidium 
infection in humans came to prominence after the discovery of the human 
immunodeficiency virus (HIV) in the 1980’s.  The Centers for Disease Control and 
Prevention (CDC) reported several cases of untreated chronic and prolonged diarrhea 
caused by Cryptosporidium infections in acquired immunodeficiency syndrome (AIDS) 
patients ("Cryptosporidiosis: assessment of chemotherapy of males with acquired 
immune deficiency syndrome (AIDS)," 1982).  In the same decade several cases of 
shorter term, self-resolving diarrheal cases of cryptosporidiosis in 
immunocompromised patients were also described, along with transmission of the 
parasite to humans from infected farm cattle ("Human cryptosporidiosis--Alabama," 
1982; Reese, Current, Ernst, & Bailey, 1982).  In the developing world, 
cryptosporidiosis was reported not only to be a common cause of chronic diarrhea, but 
also associated with malnutrition in young children (Macfarlane & Horner-Bryce, 
1987).   
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Research in the field was still highly limited until the United States’ largest 
recorded waterborne outbreak caused more than 400,000 people to fall sick with 
cryptosporidiosis in Milwaukee in 1993 (Mac Kenzie et al., 1994).  Despite numerous 
reports documenting cryptosporidiosis in immunosuppressed children in developing 
countries, Cryptosporidium was not considered a major pathogen until most recently 
after the report of the Bill and Melinda Gates Foundation funded the Global Enteric 
Multicenter Study (GEMS) (Kotloff et al., 2013).  GEMS was the largest and most 
comprehensive study of childhood diarrhea, involving seven sites in Africa and Asia, 
and it identified cryptosporidiosis as the third most common cause of severe diarrhea in 
young children (J. Liu et al., 2016).  The GEMS study used more sensitive detection 
techniques to identify Cryptosporidium species and corrected for co-infections with 
various other pathogens to find the pathogen responsible for the disease (Kotloff et al., 
2013; J. Liu et al., 2016).  Cryptosporidiosis was not considered a major pathogen for a 
long time and hence, the true extent of spread had never previously been thoroughly 
examined.  All these factors combined with the fact that the earlier human studies have 
used less-sensitive methods of detection (Chalmers & Katzer, 2013) make it difficult to 
comprehend the true extent of infection. 
 
1.3.  Transmission 
The predominant mode of infection is thought to be the fecal-oral route, as 
several logs per gram of environmentally stable oocysts are shed in the feces of infected 
individuals and calves, and as little as 9 oocysts of some virulent strains are sufficient 
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to cause disease in ~50% of the healthy volunteers (ID50) (DuPont et al., 1995).  The 
thick-walled oocysts shed in the feces are also highly stable in water for several months 
and are resistant to bleach, making water treatment complicated in developed countries 
as well (Rose, Huffman, & Gennaccaro, 2002).  This has led to several outbreaks in the 
US and Europe, including the Milwaukee outbreak in the US that was mainly caused 
due to malfunction in the municipal water filtration unit.  Frequent outbreaks in 
developed countries also occur due to infections from recreational water in swimming 
pools and playgrounds (Hlavsa et al., 2011).    
C. parvum and C. hominis are the Cryptosporidium species that account for 
more than 90% of the infections in humans (Cacciò, 2005; Checkley et al., 2015).  C. 
hominis is the species that is associated with majority of the waterborne outbreaks and 
was also responsible for most of the infections in children in the GEMS study (Sow et 
al., 2016).  Although C. hominis can infect calves as well (Akiyoshi, Feng, Buckholt, 
Widmer, & Tzipori, 2002), C. hominis infections in humans are thought to be 
predominantly spread from other symptomatic and/or asymptomatic human carriers 
(Chalmers & Katzer, 2013; Hunter & Thompson, 2005).   On the other hand, C. parvum 
can be transmitted from infected calves and humans (Hunter & Thompson, 2005). 
 
1.4.  Epidemiology 
1.4.1.  Children 
Diarrhea is the second leading cause of death in children below 5 years of age, 
causing more than 499,000 deaths in 2015 (Disease, Injury, & Prevalence, 2016).  
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Shockingly, this is similar to the number of deaths due to all the cancers combined in 
the United Sates (U.S. Cancer Statistics Working Group, 2017).  Although the number 
of deaths caused by diarrhea is on a steady decline, the decrease in incidence of 
diarrhea has been marginal, with the low- and middle- income regions of South Asia 
and sub-Saharan Africa worst affected  (Disease et al., 2016; Mortality & Causes of 
Death, 2016).  Cryptosporidiosis is a leading cause of infectious diarrhea in children 
(Kotloff et al., 2013; Jie Liu et al., 2016; Platts-Mills et al., 2015).  Apart from being 
fatal, diarrhea is detrimental to the health of children, leading to long term 
developmental and growth defects (Bushen et al., 2007; Guerrant et al., 1999; Korpe et 
al., 2016; Kotloff et al., 2013).  There is also a strong correlation between 
Cryptosporidium infections and malnutrition in children, although it is not clear if 
cryptosporidiosis is the predominant cause of malnutrition or if malnourished children 
are predisposed to cryptosporidiosis; both may be true (Macfarlane & Horner-Bryce, 
1987; Shirley, Moonah, & Kotloff, 2012).  It is also not known if during infections in 
infants, especially malnourished and immunocompromised children, the disease is only 
limited to the gastrointestinal tract. 
 
1.4.2.  Immunocompetent and Immunocompromised Adults 
Cryptosporidiosis is self-limiting in immunocompetent adults, with infections 
ranging from asymptomatic to 2 weeks or longer of diarrhea (Chen, Keithly, Paya, & 
LaRusso, 2002).  The infections are predominantly limited to the gastrointestinal tract 
with only a few cases of extra-intestinal infection reported in immunocompetent 
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patients with C. hominis (Hunter et al., 2004).  In contrast, the infection is more likely 
to extend beyond the intestine in individuals with limited or no cell-mediated immunity, 
like AIDS patients and organ transplant recipients (Chen et al., 2002; Malebranche et 
al., 1983; Navin et al., 1999).  The biliary tract usually gets infected in these patients 
and is thought to be a reservoir of infection (Chen et al., 2002).  Most AIDS patients 
experience prolonged diarrhea, which lasts more than two months.  Only about 4% of 
the patients shed the parasite without showing diarrhea symptoms.  The symptoms in 
AIDS patients are inversely proportionate to the CD4+ T-cell counts, and treatment 
with highly active anti-retroviral therapy (HAART) can restore health (Flanigan et al., 
1992).  
 
1.5.  Life Cycle 
Cryptosporidium completes its life cycle in one host (monoxenous) (refer 
Figure 1 for schematic).  The ingested thick-walled oocysts are triggered for 
excystation by the acid in the stomach followed by the bile salts, temperature and pH 
change in the intestine.  A suture in the oocyst wall opens to release the infectious 
motile sporozoites.  Sporozoites attach and invade the intestinal epithelial cells lining 
the lumen to form an unusual intracellular but extra-cytoplasmic niche called the 
parasitophorous vacuole (PV).  This niche gives the parasite the advantage to steal 
nutrients from the lumen of the intestine as well as the cytoplasm of the host cell.  The 
initial uninucleate intracellular form is called a trophozoite.  The trophozoites undergo 
asexual replication (merogony) to form type I meronts, each containing six to eight 
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merozoites.  The merozoites egress out of the PV to infect more epithelial cells.  Each 
merozoite is thought to form a new trophozoite that can undergo merogony to form 
type I or type II meronts (containing only 4 nuclei).  Type I meronts are thought to 
repeat the asexual replication cycle, while Type II meronts are believed to give rise to 
the sexual stages of microgamonts and macrogamonts.  Each microgamont contains 
several motile microgametes (sperm equivalent), which upon release find and fertilize 
the uninucleate macrogamont (egg cell equivalent) to form thin- or thick-walled oocysts 
that sporulate in situ.  The thin-walled oocysts are presumed to cause further local 
infection in the same host, while thick-walled oocysts are secreted in the feces for 
dissemination (Current & Reese, 1986; Fayer & Xiao, 2007).  The life-cycle of 
Cryptosporidium is primarily based on visualization of stages using histology and/or 
electron microscopy techniques, and has not been validated by genetic or molecular 
approaches. 
 
1.6.  Current Treatment Options 
There are no vaccines for cryptosporidiosis.  The only U.S. Food and Drug 
Administration (FDA) approved medicine, nitazoxanide, has variably efficacy, with 
poor activity in the most affected populations.  A placebo controlled study in HIV 
positive patients with cryptosporidiosis showed nitazoxanide to be completely 
ineffective (Abubakar, Aliyu, Arumugam, Hunter, & Usman, 2007).  In a study with 
malnourished children with chronic cryptosporidiosis, nitazoxanide cured the diarrhea 
symptoms at day 7 in 56% of the patients, as opposed to the 23% of cured cases with 
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placebo alone (B. Amadi et al., 2009).  Nitazoxanide is most effective in 
immunocompetent individuals, in whom it speeds up recovery (Beatrice Amadi et al., 
2002).  Paromomycin has shown good efficacy in mouse models of cryptosporidiosis, 
but is not useful in AIDS patients with cryptosporidiosis.  Several other molecules 
including azithromycin, spiramycin, and immunoglobulin have proven ineffective 
against cryptosporidiosis in AIDS patients (Cabada & White, 2010; Checkley et al., 
2015).  Even with HAART therapy in AIDS patients, significant mortality is observed 
early on (Dillingham et al., 2009).   Halofuginone is approved in Europe for use as a 
prophylactic drug for cryptosporidiosis in calves (Trotz-Williams, Jarvie, Peregrine, 
Duffield, & Leslie, 2011), but not in humans, due to its toxicity and side effects (Pham 
et al., 2014).  There is a clear and desperate need for better treatments for 
cryptosporidiosis in the most vulnerable populations. 
 
1.7.  An Overview of Drug Discovery and Development 
A general drug discovery and development scheme involves multiple stages that 
progress from identifying an active compound in vitro to activity in animal models to 
patient populations.  Drug development generally happens at a pharmaceutical 
company wherein the efforts are well coordinated between diverse groups of people 
with specific expertise who are provided with clear go/no-go decisions set at every 
stage of drug development.  An overview of the key stages is discussed below. 
The initial discovery phase starts with a basic R&D exploratory stage that 
requires understanding biology of the disease.  This is followed by development of a 
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reliable and robust screening assay with a goal to obtain diverse chemical scaffolds 
with desired activity against the disease.  When available, a high-throughput screening 
assay is generally preferred, which could be a target-based or phenotype-based 
screening assay.  In the phenotype-based approach, a collection of small molecules is 
tested for their effect on a biological process, for example, inhibition of asexual 
replication of a parasite in an in vitro cell based assay.  On the other hand, a target-
based approach involves screening of small molecules that alter the activity of a natural 
or recombinant protein that is crucial to the disease.  The second approach requires the 
target be validated and activity of the molecules reconfirmed against intact cells.  
Although several recent advancements in genomics and computer-based modelling 
have dramatically aided target-based screening, it is unclear which of the screening 
approaches is more productive, as several successful drugs have been developed with 
both methodologies and it is not mandatory to know the target for a drug to be 
approved. 
Screening data are analyzed to identify molecules with desired effects (hits). 
The hits need to be further validated based on biological, physical and chemical 
properties.  Drug development in general has a very high attrition rate that depends a lot 
on the quality of the initial molecules.  Furthermore, the investment for drug 
development increases dramatically following hit identification, demanding 
prioritization of quality hits.  Prioritized hits with favorable pharmacodynamic (PD) 
and pharmacokinetic (PK) properties are tested for toxicity and efficacy in an animal 
model, which hopefully gives rise to an early lead molecule.  The early leads undergo 
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several rounds of structural optimization for selectivity, potency, and PK-PD among 
other parameters to give rise to a drug candidate.  
The drug candidate is further developed and tested in the preclinical 
development stage.  This stage includes the study of process chemistry factors such as 
assessment of cost of goods, compound stability and further comprehensive preclinical 
safety studies in animals under Good Laboratory Practices (GLP) conditions.  Once an 
investigational new drug application (IND) has been successfully accepted by a 
regulatory agency such as the US FDA, the molecule goes into preliminary Phase I 
clinical trials.  Upon successful completion of Phase I, dosing regimens are optimized 
in Phase II, followed by a study against the comparator product in Phase III.  If the 
molecule is successful in the clinical trials, a Marketing Authorization Application 
(MAA) is submitted to request full approval.  There are numerous reasons that drug 
candidates fail.  The lack of efficacy has contributed to 21% of the failures, while 21% 
have failed due to toxicity.  Biopharmaceutical properties like oral bioavailability and 
formulation issues account for 39% of failures (Nwaka & Ridley, 2003). 
The Cryptosporidium drug development pathway is not very well established 
(Huston et al., 2015; Manjunatha, Chao, Leong, & Diagana, 2016), with the first 
medium-throughput phenotypic screening assay published in 2013 (Bessoff, Sateriale, 
Lee, & Huston, 2013).  The following sections are going to discuss some of the key 
aspects of the initial stages of drug development up to lead identification successfully 
used for other neglected infectious diseases, followed by a discussion of how these 




1.8.  Neglected Disease Drug Development 
Neglected tropical diseases (NTDs) are a group of infectious diseases that 
predominantly affect low-income populations in the less-developed world.  The 
infections are widespread, causing severe morbidity and mortality while also costing 
developing economies billions of dollars every year.  The lack of a market incentive 
along with challenging drug R&D and the high financial cost of drug development has 
hindered pharmaceutical investment for NTDs.  Although NTDs account for more than 
11% of the global disease burden, less than 1% of the approved drugs from 1975-2004 
were for neglected tropical diseases (Trouiller et al., 2002).  Since then, the formation 
of public-private partnerships (PPPs) and product development programs (PDPs) along 
with philanthropic and government funding has significantly improved the efforts 
towards developing therapeutics for NTDs.  The PDP model involves a collaborative 
approach for drug development.  PDPs essentially provide the oversight framework for 
drug discovery and development in a non-profit neglected disease setting.  They 
provide structure in the form of disease specific goals based on patient needs, facilitate 
key collaborations fostering sharing and openness, and require standardized assays that 
enable logical go/no-go decisions, which results in appropriate prioritization and 
resource distribution.  Some of the salient strategies used by PDPs like the Medicines 
for Malaria Venture (MMV), TB alliance, the Drug development for Neglected Disease 
Initiative (DNDi) for Chagas and visceral leishmaniasis are discussed below (Katsuno 
et al., 2015). 
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Setting clear goals for NTD drug development by understanding patient 
populations and needs has been successful in many instances.  Target candidate profiles 
(TCP) are put in place to guide development of new molecules and target product 
profiles (TPP) for new medicines (Katsuno et al., 2015).  There can be multiple TPPs 
and TCPs, and these keep evolving based on the need, since drug development usually 
takes a decade to complete during which disease landscape and patient needs can 
change, and major technological improvements in drug development may occur.  For 
example, malaria drug development has two TPPs and five TCPs, with TCPs used to 
prioritize hits based on rate of action of compounds and life stage activity with clear 
gold standards used for every assay (Burrows et al., 2017; Burrows, van Huijsduijnen, 
Mohrle, Oeuvray, & Wells, 2013).  The TPP for TB focuses on developing new drugs 
that are active against the drug-sensitive and drug-resistant TB, and reduce the duration 
of current treatments (Katsuno et al., 2015).  The minimum requirement for visceral 
leishmaniasis includes greater than 90% clinical efficacy in a ten-day treatment regimen 
with activity against all resistant strains of L. donovani, along with no drug-drug 
interaction issues with malaria, TB and HIV treatments (Chatelain & Ioset, 2011).  The 
TPP for Chagas disease at a minimum demands superiority to the current standard of 
care, benznidazole (Chatelain & Ioset, 2011).  The presence of a gold standard drug has 
greatly helped set clear goals for TPPs and TCPs for these diseases. 
Apart from the high-cost, there are several unique challenges facing drug 
development for NTDs.  A high proportion of the patients reside in areas with poor 
infrastructure and highly limited healthcare resources.  Therefore, the drugs need to be 
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stable under high-temperature and humidity conditions for long durations.  
Furthermore, drugs should be administered with no or limited oversight for dosing.  
Hence, oral drugs with minimal doses are favored.  Co-infections are common in the 
tropical areas requiring a potential for multiple treatments at the same time requiring 
drugs with low drug-drug interactions so that there is no interference with other 
medicines.  
 
1.8.1.  Assay development 
In general, it is unclear if target or phenotype-based screening is more fruitful 
(Eder, Sedrani, & Wiesmann, 2014; Swinney, 2013).  There are several advantages to 
using a target-based screen.  The knowledge of a target is exceptionally helpful in that 
it can aid in optimization of a chemical scaffold for selectivity towards the pathogen 
over the human host.  Medicinal chemistry is also much easier to perform to improve 
potency, pharmacokinetic and pharmacodynamics properties.  Knowledge of the target 
at the start can also help predict any toxicity issues that might come up later in the 
process.  In disease areas where drugs with different mechanisms of action are desired, 
it is beneficial to know the target.  Genome sequencing considerably eased the process 
for target identification, but target validation can be challenging, especially in the case 
of poorly studied NTDs.  Furthermore, there is an added requirement to test the 
feasibility of the compound against the intact whole pathogens.  In some cases, 
discrepancies have been observed between in vitro target inhibition studies and activity 
against whole pathogens for NTD drug development.  There could be discrepancies 
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between activity against a target versus whole cell due to several reasons, such as 
inaccessibility of the target due to membrane permeability issues, off-target effects, 
alternate compensatory pathways, etc. (Nwaka & Hudson, 2006).  
On the other hand, phenotypic screens are performed against the whole 
pathogen.  Phenotypic screens are not biased and have the potential to quickly provide a 
large number of diverse hits, although the success of the hit and its druggability cannot 
be determined until later on.  Recent improvement in genetics and molecular biology 
techniques, especially omics technologies, can aid in figuring out targets after 
phenotypic screening.  Furthermore, phenotypic assays have been more productive for 
anti-bacterial drug development (Payne, Gwynn, Holmes, & Pompliano, 2007).  
Phenotype-based screens also provide a resource to screen and identify hits from a 
larger chemical space as compared to target-based screens.  For these reasons, 
phenotypic screens have been more widely used for NTDs.  For an efficient and reliable 
high throughput screen (medium throughput screen at the minimum), the assay needs to 
be robust with a good signal to noise ratio, which is often assessed using statistical 
metrics such as the Z and Z’ scores (Zhang, 1999).  Apart from the primary screening 
assay, several other follow-up assays aide in prioritization of hits with respect to TCPs 
and TPPs.   
The in vitro culture of asexual blood stages of all major species of Plasmodium 
has been extremely important for malarial drug development (Schuster, 2002).  Further 
breakthroughs in assays for the different life stages have been key in obtaining diversity 
and addressing specific needs such as activity against liver stages of species that 
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establish dormancy (Burrows et al., 2013).  To directly compare compounds and avoid 
discrepancies between groups, MMV contracts out each of these assays to experts at 
specific locations for testing all the molecules under similar conditions.  
 
1.8.2.  Screening compound source  
The quality of starting chemical entities is extremely important, especially for 
NTDs, wherein there is an urgent medical need, but the resources are highly limited.  
Pharmaceutical and biotech companies have a rich source of unique chemical 
compounds and associated expertise.  PDPs utilize the collaborative model, wherein 
pharmaceutical and biotech industries contribute sets of diverse small molecules 
containing annotated analogues along with the knowledge and expertise associated with 
it (Chatelain & Ioset, 2011).  MMV has also gone a step further and put together 
libraries of compounds with analogues from pharmaceutical companies and made them 
freely available for NTD research.  To add further value, MMV asks for the screening 
data to be made available to the public in return for the compounds.  The libraries 
include the ‘Malaria Box’, which is a set of 400 unique and diverse compounds active 
against blood stage of P. falciparum from phenotypic screens of over 6 million 
compounds performed by GlaxoSmithKline (GSK), the Genomics Institute of the 
Novartis Research Foundation (GNF), and St. Jude Children's Research Hospital (Van 
Voorhis et al., 2016).  Furthermore, all the 400 compounds are commercially available 
and there is significant data shared for safety including: host cell toxicity using several 
cell lines and zebrafish; absorption, distribution, metabolism and elimination (ADME); 
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PK; and activity against several different pathogens.  MMV has also recently put 
together a ‘Pathogen Box’, which includes 400 molecules with activity against at least 
one of several different pathogens that cause NTDs, including malaria, TB, 
kinetoplastids, helminths, cryptosporidiosis, toxoplasmosis and dengue virus (Duffy et 
al., 2017).  Similar to the Malaria Box collection, significant investment has been made 
for these compounds, with data for host cell toxicity, ADME properties and PK made 
available.  These data are extremely valuable for follow-up, saving time and resources 
while accelerating drug development for NTDs.  For some of the compounds the 
biological targets are known, and this can aid in use of these molecules as chemical 
probes to explore the biology of the less-studied NTDs.  PDPs have also initiated 
collaborations with pharmaceutical companies to obtain libraries of classes of inhibitors 
along with analogues that inhibit a specific known biochemical pathway of importance 
(Chatelain & Ioset, 2011). 
There has been some success in repurposing existing drugs or compounds with 
significant previous investment for NTDs, especially compounds that have been taken 
into clinical trials, as it reduces the associated financial risk.  For example, eflornithine 
was initially developed as an anti-cancer drug, but was later found to have great activity 
for treating Human African Trypanasomaisis (HAT).  Miltefosine was initially taken to 
human trials for its anti-cancer properties, but then was taken for clinical trials for 
leishmaniasis due to its superior efficacy compared to existing treatments in the rodent 
model (Andrews, Fisher, & Skinner-Adams, 2014).  The NIH clinical collection library 
serves as a useful source for repurposing, as it is composed of FDA-approved drugs and 
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molecules that have been taken into clinical trials (Bessoff et al., 2013).  A major 
concern with repurposing already existing profit-making drugs is that the companies 
owning the drugs could be unwilling to share them in fear of identification of new 
safety concerns or other issues that might affect existing use (Pink, Hudson, Mouries, & 
Bendig, 2005).   
 
1.8.3.  Hit Identification 
Phenotypic screens against the whole pathogen make it possible to screen 
thousands to millions of compounds in a short amount of time.  There is no single 
formula or global potency threshold cut-off to identify hits from the screens, as the 
potency depends on several factors, including the assay type, assay set-up conditions 
(serum concentration, detection methods, compound concentration etc.), nature of the 
chemical library, and the pathogen under study.  Several assays can be used as primary 
screens that can yield different results.  For visceral leishmaniasis, a direct comparison 
of the axenic assays with adapted extracellular amastigotes that are thought to mimic 
intracellular stages gave a higher false-positive hit rate than the L. donovanii amastigote 
intracellular assay (De Rycker et al., 2013).  The P. falciparum intracellular blood stage 
assay is the most widely used assay for primary screening for malaria.  But the different 
TCPs could require alternate primary screening assays, like a malaria liver 
schizonticidal assay used to identify compounds active against latent liver stages that 
complicate treatment of malaria (Burrows et al., 2017; Burrows et al., 2013).  PDPs 
18 
 
focus towards standardizing primary screening or follow-up potency assays for disease 
types so that compounds identified from various sources can be directly compared. 
The hit cut-off can vary dramatically between pathogens due to differences in 
the biology of the diseases.  For example, asexual blood stages of Plasmodium involve 
processes like host membrane re-arrangement that are targeted by the general drug-like 
molecules.  On the other hand, L. donovanii has its intracellular stage inside acidic 
compartments of the phagolysosome of macrophages that are hard to access and retain 
drug activity in (Katsuno et al., 2015). 
 
1.8.4.  Hit Validation 
The initial hits from the primary screen need to be further tested for several 
general and disease specific parameters to be considered a validated hit.  The 
compound needs to be re-synthesized/re-purified with a conventionally decided purity 
of greater than 90% and tested against the pathogen to confirm its activity.  Dose 
response curves should be performed against the pathogen to determine the half-
maximal inhibitory concentration (EC50), with the compound able to attain 100% 
inhibitory activity (usually demonstrating a sigmoidal concentration versus growth 
inhibition curve with a Hill coefficient ideally between 0.5 and 1.8).  Potency varies 
with disease with a reasonable cut-off selected based on other compounds identified.  
For example, for malaria where it has been relatively easy to identify hits, a cut-off of 
1-2 µM is used (Gamo et al., 2010; Guiguemde et al., 2010; Plouffe et al., 2008).  It 
should be noted that potency has little to do with potential efficacy, but has a large 
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impact on manufacturing costs.  The molecule should have at least greater than a 10-
fold selectivity window over a relevant mammalian cell line.  Keeping in line with 
lower manufacturing costs, the molecule should be easy to synthesize, ideally in less 
than 5 steps with acceptable yield.  Preliminary structural-activity relationship studies 
(SAR) should show potential for medicinal chemistry changes and the molecule should 
not have any unstable or highly reactive moieties in the core pharmacophore (Katsuno 
et al., 2015; Nwaka & Hudson, 2006; Nwaka et al., 2009).   
 
1.8.5.  Hit-to-lead and Early Lead Identification 
An early lead compound should demonstrate acceptable in vivo PK, toxicity and 
efficacy in a relevant animal model of the disease.  The hit-to-lead prioritization is an 
extremely crucial step in NTD drug development as the finances, time and resources 
are highly limited.  Added on, the high attrition rate of drug development is inversely 
proportionate to the quality of the chemical entities.  Furthermore, since the investment 
in cost and time dramatically increases as one goes further in drug development, it is 
critical that quality lead compounds are prioritized (Khanna, 2012; Nwaka & Hudson, 
2006).  Hit-to-lead prioritization is generally guided by clear go/no-go decisions based 
on the TPPs and TCPs.  In general, a diverse set of molecules with different 
mechanisms of action are preferred, as this gives a better chance for at least one 
molecule to make it all the way, rather than prioritizing all compounds with similar 
profiles (Katsuno et al., 2015). 
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For example, malarial drug development has clear TCPs based on life stage 
mechanism of action studies.  The validated hits are screened against all the life stage 
assays along with key mechanistic assays and these results are used for further 
prioritization of compounds.  The presence of gold standard compounds for comparison 
in each assay dramatically helps in characterizing the compounds (Burrows et al., 2017; 
Burrows et al., 2013). 
The choice of in vivo model is extremely important.  This was particularly true 
for a recent promising drug candidate, posaconazole, for Chagas disease.  Posaconazole 
was highly promising in vitro, in an animal model for Chagas and preclinical efficacy 
studies.  It also had a different mode of action from the only approved class of 
nitroheterocyclics.  But the compounds failed during clinical treatment, as it performed 
poorer than the approved benznidazole nitroheterocycle class.  Looking back, 
posaconazole was only tested in the acute disease mouse model, while the chronic stage 
is an important cause of disease, underscoring the importance of using the correct 
models (Chatelain, 2015; Molina et al., 2014). 
 
1.9.  Anti-Cryptosporidium Drug Development 
The only FDA approved drug for cryptosporidiosis, nitazoxanide, is not very 
effective in young children and immunocompromised patients, but the reasons for its 
failures are not known.  The lack of a highly efficacious drug complicates drug 
development, since there is no standard to follow.  
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Cryptosporidium biology is poorly understood, as there is no continuous in vitro 
culture system.  A few rounds of asexual replication followed by formation of gamonts 
can be achieved in vitro, after which the culture crashes.  Based on visualization 
techniques, it is thought that the parasite needs to undergo asexual followed by sexual 
replication to sustain an infection in vivo, but such details of the life cycle have not 
been confirmed by genetics or molecular methods.  Based on the few rounds of asexual 
growth in vitro, a medium-throughput cell based phenotypic screening assay using the 
C. parvum Iowa isolate was developed for the first time and published in 2013.  Prior to 
this, most of the drug development efforts were hypothesis driven or random, with a 
few groups taking advantage of genomic data and using target-based screening efforts.  
Due to the lack of genetic tools for Cryptosporidium, none of the targets were 
effectively validated.  After the GEMS reports demonstrating cryptosporidiosis as a 
leading cause of severe diarrhea in children, there has been a lot of interest in 
Cryptosporidium drug development efforts including from pharmaceutical companies, 
and funding from the Bill and Melinda Gates Foundation.  PATH, a non-profit 
organization, has also started an accelerator for Cryptosporidium research and drug 
development to reduce child mortality (ACCORD) program to facilitate the 







1.9.1.  Target Product Profile 
The first TPP for cryptosporidiosis was published by Huston et. al. in 2015 
(Huston et al., 2015).  This has been followed up by a slightly modified TPP put 
forward by Majunatha et. al. in 2016 (Manjunatha et al., 2016), demonstrating the 
evolving nature of the TPPs.  The profiles are predominantly similar with major 
differences in the duration of desired treatment regimen, method of treatment, and 
desired microbial and clinical efficacy, including extra-gastrointestinal infections.  Both 
the publications put forward minimum and ideal TPPs for cryptosporidiosis.  Since 
developing drugs and performing clinical trials on infants < 6 months of age is 
complicated, the initial idea is to first focus on C. hominis or C. parvum infected infants 
6-24 months old that do not have HIV.  It is assumed that a drug effective in infants 
would also work in immunocompetent children and adults. Ideally, the target 
populations would include children greater than 1 month of age with or without HIV 
and immunocompromised adults.  Huston et. al. recommends a new drug should at least 
have microbial (clear fecal parasite shedding) and clinical efficacy (resolution of 
clinical diarrhea symptoms) that is superior to nitazoxanide in malnourished children, 
and similar to nitazoxanide in immunocompetent individuals.  Ideally, the drug should 
be able to clear fecal parasite shedding quickly (e.g. < 2 days) and have > 90% efficacy 
in all patient populations.  Manjunatha et. al. suggest that the drug needs to show 
clinical and microbial efficacy by 4 days of treatment with > 90% efficacy in the 
minimum target population and > 95% efficacy in the ideal case target population with 
clearance of extra-gastrointestinal infections.  Microbial efficacy is achieved when fecal 
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parasite test is negative for 2 consecutive days.  Huston et. al., recommend an oral 
treatment that is at the minimum of superiority over nitazoxanide in the vulnerable 
populations, while ideally a single dose cure is preferred.  Manjunatha et. al., call for a 
3-day dosing cure with a maximum of thrice a day dosing regimen, and acceptance of a 
parenteral dosing regimen in a hospital setting.  Based on market analysis and the 
desired public health benefit, the cost of the complete treatment should not be more 
than US$2.00, which is the cost of a complete treatment with nitazoxanide in India.  
Ideally, the treatment should cost US$0.50 (Huston et al., 2015). 
 
1.9.2.  Hit Identification and validation 
The medium-throughput screening assay has been further optimized by the 
California Institute for Biomedical Research (Calibr) into a high-throughput screening 
assay with more than 1,000,000 compounds screened to date ((Love et al., 2017) and 
personal communication).  There are several different assays developed along with 
different isolates of C. parvum Iowa strain used for potency studies (Bessoff et al., 
2014; Castellanos-Gonzalez et al., 2013; Chao et al., 2018; Gorla et al., 2014; Love et 
al., 2017; Manjunatha et al., 2017; Ndao et al., 2013).  The differences between assays 
or a standardized assay needs to be finalized in order to directly compare hits and leads.  
With the lack of a better standard, in vitro potency requirements are based on 
nitazoxanide with a recommended EC50 equal to or less than that of nitazoxanide along 
with at least a 10-fold selectivity window against the HCT-8 mammalian cell line that 




1.9.3.  Hit-to-lead and Early Lead Identification 
C. parvum Iowa isolates have been passed in calves with several logs of oocysts 
shed per gram feces during peak infection.  This has provided a constant supply of 
oocysts for in vitro studies, as the parasite cannot be continuously cultured using a 
simple in vitro system (Arrowood, 2002).  On the other hand, the laboratory strain of C. 
hominis, TU502 whose genome has been sequenced, has been maintained in 
gnotobiotic piglets that require expensive special housing and maintenance with poorer 
yields compared to calves.  Furthermore, isolated C. parvum oocysts are stable at 4 °C 
for up to 4-5 months in phosphate buffered saline, whereas, C. hominis TU502 are 
highly unstable, retaining in vitro viability only a few days after shedding.  This has 
made C. parvum the strain of choice for in vitro studies.  Even though a substantial 
portion of the human infections are caused by C. hominis.  Therefore, it is imperative 
that compounds be tested for activity against C. hominis as well.  Furthermore, the 
infectious dose and in vitro drug susceptibility for field isolates is known to vary.  
Hence, it is extremely beneficial to test hits against at least C. parvum farm field 
isolates to avoid unexpected concerns further in the drug development process. 
Learning from other NTD drug development strategies, development of several 
other assays has been suggested by Huston et. al. as part of the hit-to-lead prioritization 
cascade.  These include: in vitro rate of action; static versus cidality; tendency to 
develop resistance; and life stage activity and other mechanistic assays to differentiate 
between hits and help select a diverse set of compounds despite the lack of knowledge 
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of molecular mechanism of action (Huston et al., 2015).  Poor understanding of 
Cryptosporidium biology, unavailability of reliable markers and gold standard controls, 
lack of a continuous culture system, and asynchronous in vitro infections with mixed 
parasite populations are some of the factors that have made development of these 
assays very challenging.  It is not clear if the sexual stages of the parasite have to also 
be affected to clear an infection, and/or if the sexual stage alone can be targeted to clear 
infection.  Recently, the first report of genetic manipulation of Cryptosporidium was 
published.  The method is not very convenient yet, as it involves making mutants by 
performing surgeries in mice and maintenance of oocysts in vivo, but it provides a great 
potential to help in understanding biology and developing assays along with identifying 
and validating targets (Pawlowic, Vinayak, Sateriale, Brooks, & Striepen, 2017; 
Vinayak et al., 2015). 
Cryptosporidium has an unusual intracellular but extra-cytoplasmic niche with 
access to the intestinal lumen as well as the cytoplasm of the cell.  Generally, for 
intracellular infections drugs with good oral bioavailability are preferred as the drug 
gets absorbed and accumulates in the blood and then reaches inside the infected cells.  
For an extracellular pathogen in the intestine, it is preferred that the drug does not get 
absorbed and rather stays in the intestine and locally acts on the pathogen.  
Cryptosporidium has this in-between niche, making it unclear if a drug needs to be 
absorbed or stay in the intestine.  It is more likely that the PK characteristics desired 
will vary based on the drug and its mechanism of action.  It is very likely that the PV 
membrane is selective, allowing only certain molecules to pass through.  Also, an 
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effective anti-Cryptosporidium drug could potentially target a process in the host cell 
that is crucial for the parasite’s survival (but not critical for the host), as 
Cryptosporidium is thought to rely heavily on the host.  For extra-intestinal infections, 
systemic exposures would likely be important to clear the pathogen. 
Several acute and chronic rodent models of cryptosporidiosis have been used to 
test only microbial efficacy of hits, as the rodent models do not get diarrhea (Gorla et 
al., 2014; Love et al., 2017; Manjunatha et al., 2017; Ndao et al., 2013).  The acute 
models resolve infection after a few days, giving a small window for testing hits.  The 
chronic mouse model includes the IFN-gamma knockout model, but its infection 
outcome varies between different groups, from self-resolving to lethal infections (Love 
et al., 2017; Manjunatha et al., 2017; Ndao et al., 2013).  Nitazoxanide does not have 
any activity in the rodent models tested.  In part due to the lack of a gold standard drug, 
it is not clear which of the rodent models best reflects disease in humans.  Infection of 
calves with C. parvum is used as a clinical model for diarrhea symptoms and microbial 
efficacy (Manjunatha et al., 2017; Schaefer et al., 2016; Stebbins et al., 2018).  
Although extremely expensive, gnotobiotic piglets are used for microbial and clinical 
efficacy studies of C. hominis TU502 (Theodos, Griffiths, D'Onfro, Fairfield, & 
Tzipori, 1998). 
 
1.9.4.  Our Strategy 
A key gap exists in the nascent Cryptosporidium drug development pipeline 
between screening to identify potential starting points and testing in rodents.  As noted 
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above, methods are needed for prioritization according to the likelihood of in vivo 
success, and to maintain mechanistic diversity.  Development of such key methods is 
the focus of this thesis.  Since no gold standard drug exists and very few leads have 
been reported to date, our strategy was to collaborate and obtain as many leads as  
possible from various groups with a goal to obtain a diverse set of “learner hits and 
leads” to test and validate the value of our prioritization assays. 
Our group was the first to report a robust cell-based screening assay for 
Cryptosporidium.  We have collaborated with various groups performing target- and 
phenotype-based anti-Cryptosporidium drug development and provided a cell-based 
screening facility using our assay to directly compare the potency of all of the 
compounds (Figure 2).  We have also developed a highly immunocompromised NOD 
SCID gamma (NSG) mouse model that represents chronic cryptosporidiosis, as in 
AIDS patients, providing the ability to test the effect of a molecule on an established 
infection, and also follow-up for relapse after cessation of treatment.  In line with the in 
vitro assays, these compounds were tested in the same animal model providing for 
direct comparison between all these assays.  These results formed the basis to directly 
compare the molecules in the established in vitro prioritization assays.  Chapter two 
describes prioritization of a promising hit identified from the Malaria Box screen to an 
early lead compound with activity in the NSG and IFN-gamma knockout mouse model. 
The chapter also demonstrates that a parasite persistence assay to identify potentially 
static versus cidal compounds by comparing the rate of parasite kill in vitro is a 
valuable tool to differentiate compounds.  Chapter three describes a range of life stage 
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assays that can differentiate hits based on mode of action and can be used as a tool to 















Figure 2.  Collaborations and source of anti-Cryptosporidium hits and leads used in this thesis. 
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2.1.  Abstract 
Cryptosporidiosis causes life-threatening diarrhea in children under age five, 
and prolonged diarrhea in immunodeficient people, especially AIDS patients.  The 
standard of care, nitazoxanide, is modestly effective in children and ineffective in 
immunocompromised individuals.  In addition to a need for new drugs, better 
39 
 
knowledge of drug properties that drive in vivo efficacy is needed to facilitate drug 
development.  We report identification of a piperazine-based lead compound for 
Cryptosporidium drug development, MMV665917, and a new pharmacodynamic 
method used for its characterization.  MMV665917 was identified from the Medicines 
for Malaria Venture Malaria Box, followed by dose response studies, in vitro toxicity 
studies, and structure activity relationship studies using commercial analogues.   
Potency against C. parvum Iowa and field isolates, and C. hominis was comparable.  
Furthermore, unlike nitazoxanide, clofazimine, and paromomycin, MMV665917 
appeared to be curative in a chronic NOD SCID gamma mouse model of 
cryptosporidiosis.  MMV665917 was also efficacious in an acute interferon-γ knockout 
mouse model.  To determine if efficacy in this chronic mouse model might relate to 
whether compounds are cidal or static for C. parvum, we developed a novel in vitro 
parasite persistence assay.  This assay suggested that MMV665917 was cidal, unlike 
nitazoxanide, clofazimine, and paromomycin.  It also enabled determination of the 
compound concentration required to maximize the rate of parasite elimination.  This 
time-kill assay can be used to prioritize early-stage Cryptosporidium drug leads, and 
may aide in planning in vivo efficacy experiments.  Collectively, these results identify 
MMV665917 as a promising lead, and establish a new method for characterizing 




2.2.  Introduction 
Cryptosporidiosis, caused by infection of the gastrointestinal epithelium by 
Cryptosporidium parasites, is a major cause of life-threatening diarrhea in children, 
particularly those under 1 year of age (Kotloff et al., 2013; Liu et al., 2016; Platts-Mills 
et al., 2015).  It is also highly associated with growth stunting and developmental 
delays (Bushen et al., 2007; Guerrant et al., 1999; Korpe et al., 2016; Kotloff et al., 
2013).  Two species, Cryptosporidium hominis and Cryptosporidium parvum, cause 
more than 98% of human cases (Checkley et al., 2015).  While cryptosporidiosis 
predominantly affects children in developing countries, it is also the most important 
cause of waterborne diarrhea in the United States (Hlavsa et al., 2011), and a frequent 
cause of diarrhea in immunocompromised individuals, especially AIDS patients and 
transplant recipients, amongst whom the infection is typically prolonged and can be 
fatal (Malebranche et al., 1983; Navin et al., 1999).   
Better treatments for cryptosporidiosis are badly needed.  Nitazoxanide, the 
current standard of care, accelerates recovery in immunocompetent individuals 
(Beatrice Amadi et al., 2002).  However, nitazoxanide is only partially effective in 
children, and is no better than placebo in AIDS patients (Abubakar, Aliyu, Arumugam, 
Hunter, & Usman, 2007; B. Amadi et al., 2009).  Paromomycin, which is used as a 
positive control in rodent drug efficacy studies, is also ineffective in AIDS patients 
(Abubakar et al., 2007).  Unfortunately, the reasons for nitazoxanide and paromomycin 
failure are not known.  One possibility is that both drugs inhibit Cryptosporidium 
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growth, but do not actually kill Cryptosporidium (i.e. they may be “static” rather than 
“cidal”), depending on the host’s immune system to clear the infection. 
Several recent target- and phenotype-based screening efforts have resulted in the 
identification of multiple lead compounds with promising in vivo efficacy (Bessoff, 
Sateriale, Lee, & Huston, 2013; Bessoff et al., 2014; Castellanos-Gonzalez et al., 2013; 
Gollapalli et al., 2010; Gorla et al., 2014; Love et al., 2017; Manjunatha et al., 2017; 
Maurya et al., 2009; Murphy et al., 2010; Ndao et al., 2013; Sonzogni-Desautels et al., 
2015), but there is no established pathway for the development of effective 
Cryptosporidium drugs (Huston et al., 2015).  The lack of a reliably efficacious drug to 
serve as a benchmark and variable outcomes of existing leads in different animal 
models both complicate compound prioritization for further development, since the 
meaning of variable outcomes in different animal models and compound characteristics 
that predict efficacy are unknown.  Thus, appropriate prioritization of such compounds 
for further development is poorly defined and new prioritization methods are needed.  
Here, we report the discovery of a promising new piperazine-based drug lead for 
treatment of cryptosporidiosis by using an immunocompromised mouse model of 
prolonged infection in combination with a novel in vitro assay that is analogous to a 
classical bacterial time-kill curve assay.  By reanalyzing our prior Medicines for 
Malaria Venture (MMV) Malaria Box screening data (Bessoff et al., 2014), we 
identified MMV665917 as a highly selective Cryptosporidium inhibitor with activity 
against multiple parasite isolates.  Nitazoxanide, clofazimine, and paromomycin were 
not curative in chronically infected NOD SCID gamma (NSG) mice, but clofazimine 
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and paromomycin were effective in an acute mouse model.  On the other hand, 
MMV665917 was effective in both chronic and acute mouse models of 
cryptosporidiosis.  Measurement of the rate of parasite elimination following exposure 
to different drug concentrations enabled determination of the concentration of 
MMV665917 needed to maximize the rate of parasite elimination.  Furthermore, the 
data suggested that MMV665917 was cidal against Cryptosporidium, while 
nitazoxanide, clofazimine, and paromomycin appeared to be static.  We believe this 
parasite persistence assay has general value for Cryptosporidium drug development, 
since information from it may be useful for prioritizing early-stage drug leads, and for 
planning and understanding the results of in vivo efficacy studies.  
 
2.3.  Materials and Methods 
2.3.1.  Re-analysis of MMV Malaria Box screening data 
Previously published screening data of the MMV Malaria Box used a screening 
“hit” definition of 80% inhibition to identify potential Cryptosporidium growth 
inhibitors (Bessoff et al., 2014).  These data were re-analyzed to identify additional 
Cryptosporidium inhibitors, by assuming that the average compound in the collection 
had no effect and using a statistical approach to identify compounds that differed from 
the average.  For this, the average number of parasites per host nuclei for all 
compounds was set to zero effect.  Data for each compound were then normalized to 
this average and the difference from the population mean for each compound was 
plotted on a frequency distribution plot.  Using GraphPad Prism version 6.01, normality 
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was tested with the D’Agostino-Pearson omnibus K2 test and the 95th percentile range 
was calculated.  Inhibitors at or beyond the 95th percentile were considered hits. 
 
2.3.2.  Cell culture and parasites 
Human ileocecal adenocarcinoma (HCT-8) cells (ATCC) were cultured in RPMI-
1640 medium (Invitrogen) supplemented with 10% heat-inactivated fetal bovine serum 
(Sigma-Aldrich) and 120 U/mL penicillin and 120μg/mL streptomycin (ATCC) at 37°C 
and 5% CO2.  HCT-8 cells were used between passage 9 and 39 for all experiments.  C. 
parvum Iowa isolate oocysts were purchased from Bunch Grass Farms, (Deary, Idaho).  
Oocysts were stored in phosphate buffered saline (PBS) with penicillin and 
streptomycin at 4°C, and were used within 5 months of shedding.  C. hominis TU502 
isolate oocysts were purchased from the Tzipori laboratory (Tufts University), and field 
C. parvum isolates were kindly provided by Jennifer Zambriski (Washington State 
University) and Daryl Nydam (Cornell University). 
 
2.3.3.  Cryptosporidium growth inhibition immunofluorescence assay 
C. parvum growth inhibition was measured as previously described (Bessoff et 
al., 2013).  Oocysts were excysted by treating with 10 mM hydrochloric acid (10 mins 
at 37°C), followed by exposure to 2 mM sodium taurocholate (Sigma-Aldrich) in PBS 
for 10 mins at 16°C.  Excysted oocysts were then added to >95% confluent HCT-8 cell 
monolayers in 384-well plates at a concentration of 5,500 Iowa isolate oocysts per well.  
For C. parvum field isolates, the inoculum required to give an infection level similar to 
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that produced by 5,500 Iowa isolate oocysts per well was determined and used for 
subsequent assays of parasite inhibition.  Compounds were added just before or 3 h 
after infection, and assay plates were incubated for 48 h post-infection at 37°C and 5% 
CO2.  Wells were then washed 3 times with PBS containing 111 mM D-galactose, fixed 
with 4% paraformaldehyde in PBS for 15 mins at room temperature, permeabilized 
with 0.25% Triton X-100 for 10 mins at 37°C, washed 3 times with PBS with 0.1% 
Tween 20, and blocked with 4% bovine serum albumin (BSA) in PBS for 2 h at 37°C 
or 4°C overnight.  Parasitophorous vacuoles were stained with 1.33 µg/mL of 
fluorescein-labeled Vicia villosa lectin (Vector Laboratories) diluted in 1% BSA in PBS 
with 0.1% Tween 20 for 1 h at 37°C, followed by addition of Hoechst 33258 (Anaspec) 
at a final concentration of 0.09 mM diluted in water for another 15 mins at 37°C.  Wells 
were then washed 5 times with PBS containing 0.1% Tween 20.  A Nikon Eclipse 
Ti2000 epifluorescence microscope with an automated stage was programmed using 
NIS-Elements Advanced Research software (Nikon, USA) to focus on the center of 
each well and take a 3×3 composite image using an EXi blue fluorescence microscopy 
camera (QImaging, Canada) with a 20X objective (NA = 0.45).  Nuclei and parasite 
images were separately exported as .tif files and analyzed using macros developed on 
the ImageJ platform (National Institutes of Health) (Bessoff et al., 2013).  The only 
modification from the published macro used to count parasites was that the lower size 
threshold for parasites was decreased from 16.5 to 4 pixels (1 pixel = 0.65 µm).  Graphs 
were plotted, and half maximal effective concentration (EC50) and 90% effective 
concentration (EC90) values were calculated using GraphPad Prism software version 
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6.01.  For every C. parvum field isolate experiment, a dose response against the C. 
parvum Iowa isolate was performed simultaneously as a reference. 
Cryptosporidium hominis growth inhibition assays were performed at the 
California Institute for Biomedical Research (Calibr, San Diego, CA) using a slightly 
modified immunofluorescence assay to enable automated compound handling and the 
use of 1536-well microtiter plates (Love et al., 2017).  The HCT-8 culture medium was 
replaced with RPMI 1640 supplemented with 2% heat-inactivated horse serum, 100 
U/mL penicillin, and 100 mg/mL streptomycin 24 h prior to infection with either C. 
hominis or the C. parvum Iowa isolate as a reference.  For these assays, D-galactose 
was found to be unnecessary and was eliminated from the plate wash buffer.  Imaging 
was performed using a CellInsight CX5 High Content Screening Platform (Thermo) 
with a 10X objective and acquisition of one microscopic field per well.  Images were 
processed using HCS Studio Scan software, and the Selected Object Count (HCT-8 
cells) and Spot Count (C. hominis) were analyzed in Genedata Screener (v13.0-
Standard).  Dose response curves and EC values were calculated using the Smart Fit 
function of Genedata Analyzer. 
 
2.3.4.  Parasite persistence assay 
Excysted C. parvum oocysts were added to >90% confluent HCT-8 cells in 384-
well plates.  Compounds were added at EC50 or multiples of EC90 concentrations ~24 
hours after infection.  At ~24 h (i.e. the time of compound addition) and the indicated 
time intervals thereafter, parasites were washed, fixed, permeabilized, stained and 
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imaged as in the C. parvum growth assay.  For the extended compound exposure 
experiments, the media and compound were replaced every three days.  A separate 384-
well plate was used for each time interval.  Parasite numbers were normalized to host 
nuclei numbers and expressed as % parasite per nuclei.  In order to fit parasite decay 
curves, the effect of drugs was isolated from expected changes in parasite numbers over 
time by expressing parasite numbers as the % of DMSO control for each time point.  
Exponential decay curves were fit using GraphPad Prism software version 6.01, and 
curve validity was assessed using the replicates test. 
 
2.3.5.  Host cell toxicity assay 
Host cell toxicity was measured as previously described (Bessoff et al., 2013).  
HCT-8 cells were grown to >95% confluence in 384-well plates.  Increasing 
concentrations of compounds were added and assay plates incubated at 37°C, 5% CO2 
for 48 h.  The corner wells of each plate were trypsinized to remove cells and used as a 
blank for measuring absorbance at 490 nm.  Cell proliferation was measured using the 
CellTiter AQueous assay kit (Promega, USA) following the manufacturer’s instructions, 
and was expressed as the percent of vehicle control (DMSO).  GraphPad Prism 
software version 6.01 was used to plot graphs and calculate the concentration that 
inhibits 50% of host cell proliferation compared to DMSO control (TC50).  A selectivity 





2.3.6.  Pharmacokinetic measurements 
Mouse single-dose plasma pharmacokinetic (PK) studies were previously 
performed as part of the Malaria Box program (Van Voorhis et al., 2016), and data 
were kindly provided by the Medicines for Malaria Venture (Geneva, Switzerland).  
Three overnight fasted CD-1 male mice were each given an oral suspension of 55 
mg/kg of MMV665917 in 5% DMSO solution in 1% hydroxylpropyl methyl cellulose 
(HPMC).  Blood samples were collected at 0.083, 0.25, 1, 2, 4, 6, and 9 hours post-
treatment, transferred to microcentrifuge containing 1000 IU/mL of sodium heparin, 
and spun at 3000×g for 15 min at 4°C.   MMV665917 levels were then measured by 
liquid chromatography-tandem mass spectrometry (LC/MS/MS), using an API 4000 
AB Sciex Instruments mass spectrometer with a Phenomenex Kinetex C18 (2.6 µm × 
2.1 × 50 mm) column (phase A:  0.1% formic acid/4.9% acetonitrile/95% water; phase 
B:  0.1% formic acid/4.9% water/95% acetonitrile).  Compound spiked into control 
plasma was used as a standard. 
Fecal and intestinal content MMV665917 concentrations were measured 
following compound extraction.  Feces or intestinal contents were homogenized in PBS 
(0.1 g/mL) in a polypropylene tube and then further diluted prior to addition of an 
internal standard (enalapril) and acetonitrile protein precipitation.  The supernatant was 
then transferred to a fresh polypropylene tube and dried using a speed vac.  Samples 






2.3.7.  In vivo efficacy 
All NOD SCID gamma mouse studies were performed in compliance with animal 
care guidelines and were approved by the University of Vermont Institutional Animal 
Care and Use Committee.  Normal flora NOD SCID gamma mice (NOD.Cg-Prkdcscid 
IL2rgtm1Wjl/SzJ) (Shultz et al., 2005) were purchased from Jackson laboratory (Maine, 
USA) and housed for at least a week for acclimatization.  At 4—5 weeks of age, mice 
were infected with 105 C. parvum Iowa isolate oocysts.  Fecal oocyst shedding is 
detected 6 days after infection using a qPCR assay, so treatment was started on day 
seven after infection.  Mice (n=4 per experimental group) were treated orally (p.o.) with 
MMV665917 30 or 60 mg/kg BID, intraperitoneally (i.p.) with MMV665917 60 mg/kg 
BID, or p.o. with 1000 mg/kg BID paromomycin.  MMV665917 was suspended in 
DMSO, sonicated for 30 secs three times to get a fine suspension, aliquoted and stored 
at -80°C for less than 10 days.  On the day of treatment, DMSO aliquots of 
MMV665917 were thawed, mixed well using a vortexter and diluted with 1% HPMC 
and sonicated as before, three times for 30 secs each, mixed well and given to mice 
either p.o. or by i.p. injection.  A final 5% DMSO concentration was used in 100 µL of 
1% HPMC per dose.  For the additional malaria box compounds and compound 
variants tested, the doses were prepared in the same way and specific dosages tested are 
included in Table S3.  Mice were treated for either four or seven days as indicated, 
allowed to recover for a week and then sacrificed.  Oocyst shedding in feces was 
monitored throughout by qPCR, including relapse in infection post-treatment. 
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All interferon-gamma (IFNγ) knockout mouse studies were performed in 
compliance with animal care guidelines and were approved by Explora BioLabs (San 
Diego, CA) Institutional Animal Care and Use Committee.  Four-week old female 
normal flora C57BL/6 IFNγ-/- mice were purchased from the Jackson Laboratory and 
acclimated for three days prior to infection by oral gavage with 106 C. parvum Iowa 
isolate oocysts (Sterling Parasitology Laboratory, University of Arizona) suspended in 
sterile distilled water.  At the indicated times post infection, mice were treated with 
compound vehicle alone, clofazimine (positive control), or MMV665917.  As described 
previously, fecal parasite shedding was quantified at the indicated times post infection 
by isolating oocysts using a sucrose gradient centrifugation method (Arrowood & 
Sterling, 1987), followed by staining for immunofluorescence microscopy using a 
fluorescein isothiocyanate-conjugated mouse anti-Cryptosporidium antibody (0.25 µg 
per sample), and analysis with a Guava EasyCyte flow cytometer and CytoSoft Data 
Acquisition and Analysis software (v5.3; Guava Technologies, Inc.).  Oocyst 
counts/mL of sample were exported to Excel (Microsoft Corp.), and normalized to 
counts/mg feces.  Final data analysis and graphing were done using GraphPad Prism 






2.4.  Results 
2.4.1.  Re-analysis of the MMV Malaria Box C. parvum screen identified new 
inhibitors 
The results from the recently screened MMV Open Access Malaria Box (Bessoff 
et al., 2014) were re-analyzed using a modified hit definition.  The mean of parasite 
numbers normalized to host nuclei numbers was determined for the full library and set 
to zero.  The results for each compound were then expressed as the distance from the 
mean and used to generate a frequency distribution plot, giving rise to a normal 
distribution (Fig. S1).  Using the 95th percentile as the cutoff, 20 potential inhibitors 
were identified.  Three of the 20 compounds also affected host nuclei numbers and 
were therefore excluded from further analysis.  Fifteen of the remaining 17 were 
purchased and confirmed as selective in vitro inhibitors of C. parvum development.  
This re-analysis gave an overall hit rate of 3.75% (15/400), and yielded six 
Cryptosporidium inhibitors that were not identified in our previous study (Table S1) 
(Bessoff et al., 2014).  The parent compound and/or commercially available variants for 
eight of the fifteen Cryptosporidium inhibitors were subsequently tested in an 
immunocompromised mouse model of chronic cryptosporidiosis (Table S2).  Only 
MMV665917 was efficacious at the dose tested.  
 
2.4.2.  MMV665917 is a highly selective inhibitor of Cryptosporidium 
A piperazine-containing scaffold, MMV665917 (Fig. 1A), appeared to be a 
particularly promising new hit, since its activity was highly selective for 
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Cryptosporidium and erythrocyte-stage Plasmodium species (Van Voorhis et al., 2016).  
MMV665917 was previously reported to be inactive in numerous biological assays, 
including assays against eleven species of bacteria (e.g. Escherichia coli, Klebsiella 
pneumoniae, Salmonella typhimurium, Staphylococcus aureus, and Streptococcus suis), 
twelve protozoa, and seven helminths (Van Voorhis et al., 2016).  Based on previously 
reported toxicity profiling (Van Voorhis et al., 2016), MMV665917 was not toxic to 
zebrafish and had a selectivity index (SI) of > 20 for C. parvum over five mammalian 
cell lines.  MMV665917 was also known to have modest plasma protein binding 
(83.3% and 88.8%  for mouse and human, respectively), to have a low potential for 
significant drug-drug interactions based on low inhibition of five human and one mouse 
cytochrome P450 (CYP) isoforms (1A2, 2C9, 2C19, 2D6, 3A4-M, 3A4-T) at 10 µM, 
and to have a kinetic solubility of 18 µM at pH 7.4 (Van Voorhis et al., 2016).  The 
major known liability for development was hERG inhibition, a marker for potential 
cardiotoxicity, by 58% at 11 µM (Van Voorhis et al., 2016). 
The half maximal effective concentration (EC50) of MMV665917 against asexual 
stages of the C. parvum Iowa isolate was 2.10 µM (Fig. 1B).  There was no toxic effect 
on host HCT-8 cell proliferation at concentrations up to 100 µM (Fig. 1C), giving an SI 
of > 47.  MMV665917 displayed a similar EC50 against three C. parvum field isolates 
isolated from calves, and an EC50 of 4.05 µM against C. hominis (TU502 isolate) (Fig. 
1D).  A preliminary structure activity relationship (SAR) study using commercially 
available analogues showed that changes could be made around the piperazine linker to 
both the R and R’ groups defined in Fig. 1A without losing anti-Cryptosporidium 
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activity (Table S3; Figures S2 and S3).  Addition of a second chlorine at the meta 
position of the urea’s terminal aryl ring increased potency (Fig. 1E).  Compounds with 
an aryl urea at the R position were generally more active than aryl carboxamides, 
oxyacetamides, and sulfonamides (Fig. 1E).  It is worth noting that compounds with an 
altered substituent on the terminal aryl ring of the carboxamides and sulfonamides 
regained some potency (Fig. 1E, D-44 and D-79), suggesting options for further 
improvement of potency.  More detailed preliminary SAR are shown in Supplementary 
Figures S2 and S3. 
 
2.4.3.  Oral MMV665917 is curative in both chronic and acute mouse models of 
cryptosporidiosis 
Most prior in vivo studies of potential Cryptosporidium treatments have used one 
of several self-resolving infection models, and therefore, focused on the acute phase of 
infection (Campbell, Stewart, & Mead, 2002; Gorla et al., 2014; Love et al., 2017; You 
et al., 1998).  Others have used interferon-gamma (IFNγ) knockout (KO) mice to model 
chronic infection (Griffiths, Theodos, Paris, & Tzipori, 1998), but the results from 
different research groups are variable, ranging from lethal in some cases to self-limited 
infection in others (Griffiths et al., 1998; Love et al., 2017; Ndao et al., 2013; 
Sonzogni-Desautels et al., 2015).  In our hands, infection of IFNγ KO mice is self-
resolving (Love et al., 2017).  Therefore, to mimic chronic infection in 
immunocompromised people and afford the opportunity to assess relapse after 
treatment, we developed a new immunocompromised mouse model using NOD SCID 
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gamma (NSG) mice.  In addition to the severe combined immunodeficiency deficiency 
(SCID) defect, NSG mice lack known sources of IFNγ, including the 
monocyte/macrophage lineage and natural killer cells (Ito et al., 2002).  Our intention 
was to more cheaply mimic a previously reported model using SCID mice treated with 
an IFNγ neutralizing antibody (Tzipori, Rand, & Theodos, 1995).  Much as reported in 
that study, infection of NSG mice was reliably established by six days following oral 
gavage of 4-5 week old NSG mice with ~105 C. parvum oocysts, and asymptomatic 
fecal shedding of oocysts continued for greater than two months (data not shown). 
Paromomycin (positive control; 1,000 mg/kg oral twice daily (BID)) and 
MMV665917 (30 or 60 mg/kg oral BID) were compared in the NSG mouse 
cryptosporidiosis model with treatment of mice beginning seven days after infection.  
Mice treated for 7 days with paromomycin relapsed promptly upon cessation of 
treatment (Fig. 2A).  Twice daily 30 mg/kg MMV665917 reduced oocyst shedding by 
> 90%, but similar to paromomycin, mice treated at this dose relapsed.  Mice treated 
with MMV665917 60 mg/kg twice daily, on the other hand, were apparently cured, 
with no oocyst shedding observed at any time after stopping treatment (Fig. 2A).  As 
with the other commonly used cryptosporidiosis mouse models, nitazoxanide did not 
reduce oocyst shedding in NSG mice (Fig. 2B).  Clofazimine was also tested using 
several different vehicles, and completely lacked efficacy in the NSG mouse model 
(Fig. 2B and data not shown (various vehicles)).  This was surprising based on its 
known efficacy in an acute mouse model (Love et al., 2017). 
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To better enable comparison of results amongst different mouse models, the 
efficacy of MMV665917 30 mg/kg twice daily was directly compared to that of 
clofazimine in an IFNγ KO mouse model.  As noted above and for unknown reasons, 
C. parvum infection of IFNγ KO mice ranges from a self-resolving acute infection to 
lethal; in our hands, the infection is self-resolving (Love et al., 2017).  MMV665917 
was highly efficacious in this acute infection model (Fig. 3A and B); clofazimine 
efficacy was also confirmed. 
 
2.4.4.  Intraperitoneal dosing of MMV665917 
In hopes of determining if MMV665917 efficacy was due to intestinal or oral 
exposure, we compared the efficacy of oral and i.p. MMV665917 in the NSG mouse 
model.  MMV665917 was equally efficacious regardless of the route of administration 
(Fig. 4A).  This suggested the possibilities that: 1) MMV665917 undergoes biliary 
excretion into the intestinal lumen; 2) systemic compound concentrations drive in vivo 
efficacy of MMV665917; or 3) both. 
Fecal concentrations of MMV665917 were determined during treatment of 
cryptosporidiosis, and fecal MMV665917 levels vastly exceeded the measured EC90 
concentration regardless of the route of administration (Fig. 4B).  In fact, very high 
levels of MMV665917 were detected in the feces shortly after even a single 60 mg/kg 
i.p. dose (approximately 78× EC90 vs. 490× EC90 when given orally) (Fig. 4B).  
Following euthanasia on day 14 between 12 and 15 h after the final dose, the intestinal 
contents contained MMV665917 at many times the EC90 concentration regardless of 
55 
 
the route of administration (Fig. 4C).  Serum samples from these infected NSG mice 
treated orally or i.p. with MMV665917 were unfortunately lost during shipping.  Based 
on an independent PK exposure study in CD-1 male mice, MMV665917 plasma levels 
continued to increase for 9 hours following administration of a single oral dose of 55 
mg/kg, demonstrating that in contrast to the immediately elevated fecal levels observed, 
MMV665917 plasma concentrations build over time (Supplemental Fig. S4).  The 
possible interpretation of these data is limited, since the terminal time point was quite 
early.  Collectively, however, these data demonstrated biliary excretion of 
MMV665917, but did not provide any insight into whether MMV665917 works via 
presence in the gut lumen, the tissue, or both.   
 
2.4.5.  Rate of parasite elimination 
Adapted from classical anti-bacterial time-kill curves, we developed an in vitro 
parasite persistence assay to determine the concentration of compound required to 
achieve the maximal anti-Cryptosporidium response, and the rate of parasite 
elimination following exposure to different compound concentrations.  A similar 
approach has been applied by the Medicines for Malaria Venture to compare anti-
malaria drug candidates to benchmark compounds in immunocompromised mice 
(Angulo-Barturen et al., 2008; Burrows, van Huijsduijnen, Mohrle, Oeuvray, & Wells, 
2013).  C. parvum cannot be continuously cultured using simple in vitro methods, with 
growth in epithelial monolayers peaking at ~60 h post-infection.  In the parasite 
persistence assay, we used this narrow time window to mimic treatment of an 
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established in vivo infection by allowing infection of epithelial cell monolayers to 
progress for 24 hours prior to addition of compounds at the EC50 or multiples of the 
EC90 and then sequentially quantifying parasite numbers (schematic in Fig. 5A).    
Predicted outcomes include continued growth of control-treated parasites, or parasite 
growth inhibition versus parasite elimination for potentially static (or slowly cidal) or 
rapidly cidal compounds, respectively (Fig. 5B).  In this assay, parasites persist at the 
highest non-toxic concentrations of nitazoxanide, paromomycin, and clofazimine (Fig. 
5C and Supplemental Fig. S5).  MMV665917, on the other hand, reduced parasite 
numbers at concentrations higher than the EC90, with a maximal rate of parasite 
elimination achieved at a concentration of 3×EC90 (Fig. 5D).  However, significant 
parasite numbers remained at 72 hours following even the highest dose treatment with 
MMV665917.  To further assess if MMV665917 results in parasite elimination 
compared to paromomycin, an extended treatment experiment was performed in which 
the culture medium and drugs were replaced every three days for a total of 14 days (i.e. 
13 days of drug exposure) (Fig. S6).  As expected, parasite numbers continued to fall 
during treatment with the vehicle alone, reaching a low of ~6% of host cells infected by 
day 13.  Paromomycin treatment closely mirrored the DMSO vehicle control at five 
days of culture and beyond, but MMV665917 treatment resulted in a progressive 
decline in the percent of host cells infected to nearly zero by day 13 of treatment 
(~0.1% of host cells positive).  These data suggested that MMV665917 is cidal for C. 
parvum, while paromomycin is static. 
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Data from the parasite persistence assay were next used to estimate the in vitro 
rate of parasite elimination in the presence of MMV665917, nitazoxanide, 
paromomycin, and clofazimine.  The parasite numbers for the tested highest non-toxic 
concentration were expressed as percent of the DMSO control for each time-point in 
order to isolate the anti-Cryptosporidium effect attributable to each drug, and one-phase 
exponential decay curves were fit to calculate decay constants (Fig. 5E and 5F, and 
Supplemental Fig. S5).  Note that it was not possible to fit exponential decay curves to 
the data for nitazoxanide, paromomycin, or clofazimine (p < 0.05 for each; replicates 
test; GraphPad Prism), but a high-quality curve was readily generated for 
MMV665917.  The maximal rate of parasite elimination was achieved at 3×EC90 
concentration of MMV665917, with the rate of parasite decay similar for 3×EC90 and 
12×EC90 (decay rate constant, r = 0.05346 and 0.05864 for 3×EC90 and 12×EC90 
respectively).  The difference in the ability to fit decay curves for MMV665917, 
nitazoxanide, clofazimine, and paromomycin gave an objective indication that 
MMV665917 reduced parasite numbers under the conditions of the parasite persistence 
assay in a manner distinct from the other drugs tested.   
 
2.5.  Discussion 
The most important result of this study is the identification of MMV665917 as a 
novel, piperazine-based lead compound for treatment of cryptosporidiosis.  It is active 
against C. hominis and field isolates of C. parvum, shows no in vitro cytotoxicity at 
high concentrations, and consistent with previously published data on the MMV 
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Malaria Box (Van Voorhis et al., 2016), is highly specific for Cryptosporidium 
parasites and blood stage Plasmodium species.  MMV665917 appears to cure 
established cryptosporidiosis in highly immunocompromised NSG mice, unlike 
paromomycin (the most commonly used positive control), nitazoxanide, and the 
recently identified repurposing lead clofazimine.  It is also highly efficacious in an 
acute IFNγ KO mouse model of infection.  Interestingly, MMV665917 is efficacious in 
NSG mice regardless of dosing by oral or i.p. routes, and accumulates rapidly in the 
feces following i.p. dosing, indicating that it is at least partially excreted via the biliary 
tract.  To further understand MMV665917’s in vivo efficacy, we developed and used a 
new in vitro PD assay to measure parasite elimination vs. time at varying 
concentrations of compound.  Efficacy in the chronic NSG mouse model correlated 
with progressive parasite elimination in the presence of compound, since MMV665917 
appeared to be cidal and resulted in parasite elimination over time, while nitazoxanide, 
paromomycin, and clofazimine all appeared to be static. These features of 
MMV665917 and the methods used to define them provide guidance for further 
development of this piperazine-based compound series to treatcryptosporidiosis.  Given 
the lack of a clearly defined developmental pathway for anti-cryptosporidials, we 
believe these studies provide general guidance for Cryptosporidium drug development. 
Since MMV665917 is active against both C. hominis and a variety of C. parvum 
isolates and it is relatively specific for Cryptosporidium (Van Voorhis et al., 2016), it is 
an especially promising lead.  The in vivo efficacy studies done here, however, only 
used C. parvum and non-clinical rodent models of cryptosporidiosis.  While both C. 
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parvum and C. hominis cause human disease, and both species are also believed to be 
distributed similarly within tissues, it is important to note that the majority of children 
with life-threatening cryptosporidiosis are actually infected with C. hominis (Liu et al., 
2016).  Thus, additional early-stage testing is needed as proof of principle for in vivo 
treatment of C. hominis with MMV665917.  The gnotobiotic piglet model is the 
preferred model for such studies (Akiyoshi, Mor, & Tzipori, 2003).  Similarly, 
MMV665917 needs to be tested in a clinical model of cryptosporidiosis in which the 
host develops diarrhea, such as the dairy calf model (Manjunatha et al., 2017; Schaefer 
et al., 2016; Zambriski et al., 2013). 
Although in vitro cytotoxicity was not observed with MMV665917 for host cell 
lines and it is well tolerated in zebra fish and mice, the inhibition of hERG (58% at 11 
µM) presents a potential cardiotoxicity liability.  This is confounded by the modest 
potency of the compound versus Cryptosporidium, which suggests the possibility of a 
narrow therapeutic window in animals (Van Voorhis et al., 2016).  The results of the in 
vitro Cryptosporidium time-kill curve assay should aide in design of such studies, since 
ignoring protein binding, a concentration of compound 3×EC90 maximized the anti-
parasitic effect.  The preliminary SAR studies presented here also suggest that this 
hERG liability may be addressed through medicinal chemistry to significantly improve 
compound potency and/or reduce hERG inhibition.   Of course, such a program would 
be aided by identification of the molecular mechanism of action of MMV665917, 
which remains unknown. 
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Since MMV665917 was present in the feces regardless of administration via the 
oral or i.p. route, no conclusion is possible about the PK characteristics that drive in 
vivo efficacy (i.e. intestinal vs. systemic exposure).  This is a very important area of 
investigation for Cryptosporidium drug development in general, since the parasite 
resides in an unusual parasitophorous vacuole on the luminal surface, but enclosed 
within intestinal epithelial cells.  The fecal levels measured only provide an indirect 
view of cumulative drug exposure in the intestinal mucosa, since the fecal levels 
include both compound being eliminated and compound that is never absorbed after 
oral administration.  Furthermore, the day-to-day variability seen in Figure 4B may 
simply represent variation in drug excretion and/or fecal volumes.  The important 
conclusion from the limited PK analysis performed here is that MMV665917 is at least 
partially excreted in the feces, and presumably undergoes enterohepatic recirculation.  
Further studies to define the PK characteristics that drive MMV665917 in vivo efficacy 
are needed, and should aide in medicinal chemistry and formulation strategies for 
optimization. 
Variability in outcomes in different rodent models of cryptosporidiosis and lack 
of knowledge of the basis and significance of such variability greatly complicates 
Cryptosporidium drug development.  Our approach comparing results in chronically 
infected NSG mice to results in an acute IFNγ KO mouse model suggests that the 
chronic NSG mouse model sets a more stringent standard than acute models, since 
MMV665917 was highly efficacious in both models, but several compounds with good 
efficacy in an acute IFNγ KO mouse model were ineffective in NSG mice (i.e. 
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clofazimine, paromomycin, and data not shown).  However, it should be stressed that 
this conclusion is based on only a small number of compounds and, in any case, it 
remains unknown if such a high standard is required to achieve reliable efficacy in 
people.  In addition, we have only included data for one chronic model and one acute 
model of infection, and results may differ further amongst the other available models.  
The best pathway for developing anti-Cryptosporidium drugs is still being determined, 
and the predictive value of Cryptosporidium animal models for drug efficacy within 
different patient populations is not known.  Our data suggest that the chronic NSG 
mouse model is a model of greater stringency than the acute (i.e. self-curing) IFNγ KO 
mouse model.  As noted above, in some mouse facilities, infection of IFNγ KO mice is 
lethal (Griffiths et al., 1998; Ndao et al., 2013; Sonzogni-Desautels et al., 2015), and 
may represent a similarly high-stringency model.  In any case, there is likely value to 
prioritizing compounds in development by testing them in animal models of differing 
stringency.  A lack of efficacy in the NSG model may not preclude high-value 
compounds from advancing in development (e.g. repurposing of clofazimine); 
however, this model may help to further differentiate and prioritize the growing number 
of lead compounds that have recently been discovered.  It is logical that efficacy in a 
chronic mouse model such as the NSG model may predict drugs that will be efficacious 
for treatment of AIDS patients with chronic cryptosporidiosis and severely 
malnourished children.   
The data also suggest that efficacy in NSG mice, which lack all aspects of 
adaptive immunity, may depend on the ability of a compound to eliminate parasites in 
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the absence of a competent immune system (i.e. compound parasite killing or so-called 
cidality) and/or the rate of parasite elimination at physiologically relevant compound 
concentrations.  By quantifying parasite persistence vs. elimination in the presence of 
different drug concentrations, it is possible to determine the concentration required to 
maximize the effect of a compound.  In the absence of a simple continuous culture 
system, it is not formally possible to prove cidality on a routine basis (e.g. use of the 
recently reported hollow-fiber culture system (Morada et al., 2016) would require a 
large amount of compound and be prohibitively expensive).  However, this time-kill 
curve assay enables determination of whether a compound eliminates parasites or 
simply blocks further growth during the time frame of the assay, which likely indicates 
whether a compound is cidal or static under the conditions tested.  More importantly, 
the method is simple, inexpensive, and requires only a small amount of compound, so 
this method provides the opportunity to directly compare different compounds or 
compound classes to aide in prioritization of early-stage drug leads.  The numbers of 
compounds studied here are too few to enable an absolute conclusion, but based on our 
experience with the NSG mouse model and analogy with general principles for 
treatment of infections in highly immunocompromised individuals, it is likely that cidal 
compounds will be of the greatest value for treatment of cryptosporidiosis in the very 
patients for whom nitazoxanide is either ineffective (e.g. AIDS patients and/or 
transplant patients) or only modestly effective (e.g. malnourished children).  In this 
regard, MMV665917 is in keeping with a recently proposed ideal product profile for an 
anti-cryptosporidial drug (Huston et al., 2015). 
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In summary, we present MMV665917 as a promising lead for further 
development of an anticryptosporidial drug, and new methods with general value for 
Cryptosporidium drug development.  Current studies with MMV665917 include testing 
in a clinical model of infection in dairy calves, additional SAR studies to eliminate 
hERG inhibition and improve potency, and efforts for drug-target identification. 
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2.7.  Figure Legends 
Figure 1.  The piperazine-based Malaria Box compound, MMV665917, is a 
selective inhibitor of Cryptosporidium growth in vitro.  (A) Structure of 
MMV665917 showing a piperazine linker connecting the indicated R and R’ groups.   
(B) Dose response curve showing inhibition of intracellular C. parvum growth in HCT-
8 cells after 48 h of incubation.  Parasite numbers were normalized to DMSO vehicle 
control data.  Each point represents the mean and SD of 3 biological replicates with 4 
technical replicates per experiment.  (C) Effect of MMV665917 on proliferation of host 
HCT-8 cells as assessed by CellTiter AQueous assay (Promega).  Data are the mean and 
SD combined from 2 biological replicates with 4 technical replicates each.  (D) 
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MMV665917 activity against C. hominis TU502 and 3 different bovine field isolates of 
C. parvum.  The mean and SD of 2 independent experiments with 4 technical replicates 
per experiment are shown, except for C. hominis TU502 where mean of 3 replicates 
from 1 biological experiment is shown.  (E) Preliminary structure activity relationship 
studies using commercially available variants on R demonstrating a preference for aryl 
urea (D-28) over carboxamides (D-46, D-44), oxyacetamides (D-41), and 
sulphonamides (D-23, D-79) (see also Fig. S2 and Table S2). 
 
Figure 2.  MMV665917 cures NOD SCID gamma mice with established 
cryptosporidiosis.  (A)  Efficacy of MMV665917 compared to paromomycin (positive 
control) in NOD SCID gamma (NSG) mice.  NSG mice were infected by oral gavage 
of C. parvum Iowa isolate oocysts.  Fecal parasite shedding is detected by qPCR on day 
6, after which animals were treated with the indicated drug regimens for one week, and 
then monitored for relapse of infection (n = 4 mice per experimental group, except 
paromomycin where n = 3; data are the mean and SEM;  **, p ≤ 0.01 and ns, p > 0.05, 
by non-parametric multiple comparisons Kruskal-Wallis test for each treatment vs. 
vehicle control; BID = twice daily dosing regimen).  (B) Short-term efficacy of 
nitazoxanide, paromomycin, and clofazimine in the NSG mouse model.  NSG mice 
were infected and fecal parasite shedding was measured by qPCR as above.  Beginning 
7 days after infection, mice were treated with the indicated drug regimens.  Fecal 
parasite shedding was measured just prior to initiation of treatment and the day 
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following completion (n = 4 mice per experimental group; data are the mean and SEM:  
* indicates p ≤ 0.05 by Mann-Whitney test). 
 
Figure 3.  MMV665917 is effective in IFNγ knockout mice acutely infected with C. 
parvum.  (A) Efficacy of MMV665917 and clofazimine (positive control) in the acute 
IFNγ knockout (KO) mouse model.  IFNγ KO mice were infected by oral gavage of C. 
parvum Iowa isolate oocysts.  Compounds or the indicated vehicles were dosed as 
indicated twice daily on days 4, 5, and 6 post-infection.  Fecal parasite shedding was 
measured by isolation of oocysts using sucrose gradient flotation, followed by 
immunofluorescence staining and detection by flow cytometry. (n = 4 mice per 
experimental group).  (A) Time course comparing MMV665917 to clofazimine 
(positive control).  Data are the mean and SEM.  Horizontal dashed line indicates 
reliable limit of detection.  (B) Total fecal shedding for days 4-7.  Each symbol 
indicates an individual mouse.  GraphPad Prism was used to calculate the area under 
the fecal shedding vs. time curves.  Data are the mean and SD:  * indicates p ≤ 0.05; ** 
indicates p ≤ 0.01 by two-tailed student’s t-test. 
 
Figure 4.  Oral vs intraperitoneal (i.p.) treatment with MMV665917.  (A) Efficacy 
data measured by fecal qPCR following administration of MMV665917 at the indicated 
dose by either oral gavage or intraperitoneal (i.p.) injection.  Efficacy was independent 
of the dosing route (data are the mean and SEM; n = 4 for oral dosing; n = 3 for i.p. 
dosing; ns indicates p = 0.2 (Mann-Whitney test)).  (B) Fecal MMV665917 levels of 
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mice treated for 7 days orally or i.p. with 60 mg/kg twice daily (BID) from first 12 h of 
treatment and every 24 h thereafter.  (C) Small intestinal MMV665917 levels following 
euthanasia 12 to 15 h after the last treatment dose.  For (B) and (C) data expressed in 
µM of MMV665917 after considering 1g of intestinal contents or feces as equivalent to 
1 mL.   
 
Figure 5.  Parasite persistence assay showing in vitro elimination of C. parvum 
following MMV665917 exposure vs. parasite persistence in the presence of 
nitazoxanide.  (A) Experimental design of the parasite persistence assay.  After 
establishing an infection for approximately 24 h, compounds are added at varying 
concentrations as labeled, and then parasites and host cells are enumerated at multiple 
time points using immunofluorescence microscopy.  (B) Cartoon showing predicted 
outcomes for potentially cidal or static compounds compared to vehicle control 
(DMSO).  (C, D) Data showing parasite numbers normalized to host nuclei over time 
with increasing concentrations of (C) nitazoxanide, or (D) MMV665917.  These data 
shown are representative of 3 independent experiments (n = 4 per data point; mean and 
SD).  (E) Nitazoxanide and (F)) MMV665917 one-phase exponential decay curve fit 
using parasite persistence assay data normalized to percent of the DMSO control for 
each time point.  Data points are the mean and SD; n = 4; representative of 3 
independent experiments.  The p value is the replicates test result (note that p ≥ 0.05 




Supplementary Figure 1.  Re-analysis of MMV box screening data identifies new 
Cryptosporidium inhibitors.  The previously published screening data of 400 
compounds of the MMV box were re-analyzed (Bessoff et al., 2014).  Parasite numbers 
were normalized to nuclei and expressed as percent nuclei.  Mean of % parasite / nuclei 
was determined and each individual value subtracted from the cumulative mean to 
determine the distance from mean.  A frequency distribution plot of each compound’s 
distance from the mean gave rise to a normal distribution.  The upper 95th percentile 
concentration was set as a cut-off to identify potential inhibitors.   
 
Supplementary Figure 2.  Preliminary structure activity relationship studies using 
commercially available variants on the left-hand side R position.  The mean EC50 
for 2 biological replicates is shown, as measured against C. parvum in HCT-8 cells. 
 
Supplementary Figure 3.  Preliminary structure activity relationship studies using 
commercially available variants on the right-hand side R’ position.  The mean EC50 
for 2 biological replicates is shown, as measured against C. parvum in HCT-8 cells. 
 
Supplementary Figure 4.  Plasma pharmacokinetic information.  Male CD-1 mice 
were administered 55 mg/kg of MMV665917 orally, after which plasma levels were 




Supplementary Figure 5.  Clofazimine and paromomycin both appear to be static 
for C. parvum.  (A and B) Parasite persistence assay data for the highest non-toxic 
concentrations of (A) clofazimine and (B) paromomycin.  (C and D) Parasite 
elimination curves for (C) clofazimine and (D) paromomycin.  These data were 
normalized to the DMSO control for each time point; GraphPad Prism was used to try 
to fit a single-phase exponential decay curve.  For both drugs, it is not possible to fit a 
decay curve (replicates test; p < 0.05).  Data are representative of 3 independent 
experiments (mean and SD; n = 4 per experiment). 
 
Supplementary Figure 6.  Effects of prolonged MMV665917 vs. paromomycin 
exposure.  The parasite persistence assay was extended by replacing the media and 
compound every 3 days for a total of 14 days of infection (i.e. 13 days of drug 
exposure).  (A) MMV665917 treatment.  (B) Paromomycin treatment.  Data points are 
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a C(Nc1nc(Nc2ccccc2)nc3ccccc13)c4ccccc4 Biomolecules 326.39 4.28 1.5 (1.2-1.9)
MMV403679
a c1(c(cnn1c2cccc(C)c2)C(=O)N3)N=C3n4nc(C)cc4NC(=O)c5cc(cccc6)c6o5 SPECS 465.46 4.34 0.12 (0.10-0.14)
MMV009085 OCCCCN1C(=O)c2ccc3C(=O)N(CCCCO)C(=O)c4ccc(C1=O)c2c34 SPECS 410.42 1.01 2.6 (1.9-3.5)
MMV665852 Clc1ccc(NC(=O)Nc2ccc(Cl)c(Cl)c2)cc1Cl SPECS 350.03 5.18 3.4 (3.1-3.7)
MMV000720
a Cc1ccnc(NC(c2cccc(OCc3ccccc3)c2)c4ccc5cccnc5c4O)c1 ChemDiv 447.53 6.22 0.21 (0.17-0.27)
MMV001246
a CSc1ccccc1C(=O)Nc2nc(cs2)c3ccccn3 ChemDiv 327.42 3.38 1.8 (1.3-2.6)
MMV665814
a Oc1c(ccc2cccnc12)C(Nc3ccccn3)c4cccc(Oc5ccccc5)c4 SPECS 419.47 5.73 0.59 (0.52-0.67)
MMV665917 Clc1ccc(NC(=O)N2CCN(CC2)c3ccc4nncn4n3)cc1 SPECS 357.80 1.69 2.1 (1.9-2.3)
MMV665941
a CN(C)c1ccc(cc1)C(O)(c2ccc(cc2)N(C)C)c3ccc(cc3)N(C)C ChemBridge 389.53 4.76 0.83 (0.69-1.0)
MMV666054
a
COc1ccc(cc1)C(=O)NC(c2ccc(Cl)cc2Cl)c3cc(Cl)c4cccnc4c3O ChemBridge 487.76 6.15 0.81 (0.58-1.1)
MMV006753 CC1=CC(=O)Oc2c1ccc3oc(C(=O)c4ccccc4)c(C)c23 SPECS 318.32 4.83 0.25 (0.03-2.3)
MMV011944 n1c(NCCO)c2c(cccc2)nc1Nc3cccc(OC)c3 SPECS 310.35 2.14 3.5 (2.9-4.3)
MMV665909 Brc1ccccc1C(=O)Nc2nc(cs2)c3ccccn3 SPECS 360.23 3.59 3.3 (2.9-3.8)
MMV000760 Oc1c(CN2CCN(CC2)c3ccccc3F)cc(Br)c4cccnc14 SPECS 416.29 4.43 0.29 (0.23-0.37)
MMV665969
a
COc1cccc(c1)C(=O)NC(c2ccc(C)cc2)c3cc(Cl)c4cccnc4c3O ChemBridge 432.90 5.31 0.054 (0.041-0.070)
a 
Previously repurchased and confirmed hits from reference 1
b




Table S2.  Summary of NSG mouse efficacy experiments for Malaria Box screening 
hits. 









MMV006169 v1 C(Nc1nc(Nc2ccccc2)nc3ccccc13)c4ccccc4 Life Chemicals 50 12 4 1% HPMC
a
 / 5% DMSO No
MMV006169 v2 C1CCC(C1)Nc1nc(NCc2ccccc2)c2c(n1)cccc2 Life Chemicals 50 12 4 1% HPMC
a
 / 5% DMSO No
MMV006169 v3 COc1ccc(cc1Cl)Nc1nc(NCc2ccccc2Cl)c2c(n1)cccc2 Life Chemicals 50 12 4 1% HPMC
a
 / 5% DMSO No
MMV403679 v1 c31c(cnn1-c2cc(ccc2)C)C(=O)NC(=N3)n4c(cc(n4)C)NC(=O)c5c(cc(cc5)OC)OC Life Chemicals 100 24 7 1% HPMC
a
 / 5% DMSO No
MMV403679 v2 c31c(cnn1-c2cc(ccc2)C)C(=O)NC(=N3)n4c(cc(n4)C)NC(=O)C5CC5 Life Chemicals 100 24 7 1% HPMC
a
 / 5% DMSO No
MMV403679 v3 c31c(cnn1-c2cc(ccc2)C)C(=O)NC(=N3)n4c(cc(n4)C)NC(=O)C5CCCC5 Life Chemicals 100 24 7 1% HPMC
a
 / 5% DMSO No
MMV403679 v4 c31c(cnn1-c2ccccc2)C(=O)NC(=N3)n4c(cc(n4)C)NC(=O)c5oc6c(c5)cccc6 Life Chemicals 100 24 7 1% HPMC
a
 / 5% DMSO No
MMV403679 v5 c31c(cnn1-c2cc(ccc2)C)C(=O)NC(=N3)n4c(cc(n4)C)N Life Chemicals 100 24 7 1% HPMC
a
 / 5% DMSO No
MMV009085 OCCCCN1C(=O)c2ccc3C(=O)N(CCCCO)C(=O)c4ccc(C1=O)c2c34 - - - - - ND
MMV665852 Clc1ccc(NC(=O)Nc2ccc(Cl)c(Cl)c2)cc1Cl - - - - - ND
MMV000720 Cc1ccnc(NC(c2cccc(OCc3ccccc3)c2)c4ccc5cccnc5c4O)c1 - - - - - ND
MMV001246 CSc1ccccc1C(=O)Nc2nc(cs2)c3ccccn3 Enamine 50 12 4 1% HPMC
a
 / 5% DMSO No
MMV665814 Oc1c(ccc2cccnc12)C(Nc3ccccn3)c4cccc(Oc5ccccc5)c4 SPECS 50 12 4 No
MMV665917 Clc1ccc(NC(=O)N2CCN(CC2)c3ccc4nncn4n3)cc1 Life Chemicals 30 12 4 1% HPMC
a
 / 5% DMSO Yes
MMV665941 CN(C)c1ccc(cc1)C(O)(c2ccc(cc2)N(C)C)c3ccc(cc3)N(C)C SPECS 50 12 4 1% HPMC
a
 / 5% DMSO No
MMV666054 COc1ccc(cc1)C(=O)NC(c2ccc(Cl)cc2Cl)c3cc(Cl)c4cccnc4c3O - - - - - ND
MMV006753 CC1=CC(=O)Oc2c1ccc3oc(C(=O)c4ccccc4)c(C)c23 - - - - - ND
MMV011944 n1c(NCCO)c2c(cccc2)nc1Nc3cccc(OC)c3 - - - - - ND
MMV665909 Brc1ccccc1C(=O)Nc2nc(cs2)c3ccccn3 Enamine 50 12 4 1% HPMC
a
 / 5% DMSO No
MMV000760 Oc1c(CN2CCN(CC2)c3ccccc3F)cc(Br)c4cccnc14 - - - - - ND
MMV665969 COc1cccc(c1)C(=O)NC(c2ccc(C)cc2)c3cc(Cl)c4cccnc4c3O SPECS 50 12 4 1% HPMC
a
 / 5% DMSO No
a
















C. parvum  EC50 
(95% CI) (µM)
c
D-1 (MMV665917) Life Chemicals Clc1ccc(NC(=O)N2CCN(CC2)c3ccc4nncn4n3)cc1 357.81 2.40 78.67 2.1 (1.9-2.3)
D-2 Vitas M Labs CN1CCN(CC1)c1ccc2n(n1)c(nn2)C(F)(F)F 286.26 1.37 49.57 >25
D-3 Vitas M Labs FC(c1nnc2n1nc(cc2)N1CCN(CC1)Cc1ccccc1)(F)F 362.35 2.77 49.57 >25
D-4 Vitas M Labs CCOC(=O)N1CCN(CC1)c1ccc2n(n1)c(nn2)C(F)(F)F 344.29 1.82 75.87 >25
D-9 Vitas M Labs c1ccc(cc1)N1CCN(CC1)c1ccc2n(n1)cnn2 280.33 2.07 49.57 >25
D-12 Vitas M Labs CC(=O)N1CCN(CC1)c1ccc2n(n1)c(nn2)C(F)(F)F 314.27 0.74 66.64 >25
D-18 Life Chemicals O=C(N1CCN(CC1)c1ccc2n(n1)cnn2)Nc1ccccc1 323.35 1.72 78.67 >25
D-19 Life Chemicals O=C(N1CCN(CC1)c1ccc2n(n1)cnn2)Nc1ccc2c(c1)OCO2 367.36 1.61 97.13 >25
D-20 Life Chemicals O=C(N1CCN(CC1)c1ccc2n(n1)cnn2)NC1CCCCC1 329.40 2.48 78.67 >25
D-21 Life Chemicals O=C(N1CCN(CC1)c1ccc2n(n1)c(C)nn2)NCc1ccccc1 351.41 2.06 78.67 >25
D-22 Life Chemicals O=C(N1CCN(CC1)c1ccc2n(n1)c(nn2)C1CC1)NC1CCCCC1 369.46 2.94 78.67 >25
D-23 Life Chemicals Clc1ccc(cc1)S(=O)(=O)N1CCN(CC1)c1ccc2n(n1)cnn2 378.84 1.96 83.71 >25
D-26 Life Chemicals Fc1ccc(cc1)OCC(=O)N1CCN(CC1)c1ccc2n(n1)cnn2 356.35 1.54 75.87 20 (17-23)
D-27 Life Chemicals O=C(N1CCN(CC1)c1ccc2n(n1)cnn2)Nc1cccc(c1)C(F)(F)F 391.35 2.59 78.67 17 (14-22)
D-28 Life Chemicals O=C(N1CCN(CC1)c1ccc2n(n1)cnn2)Nc1ccc(c(c1)Cl)Cl 392.24 3.01 78.67 0.55 (0.46-0.65)
D-29 Life Chemicals Fc1ccc(cc1)C(=O)N1CCN(CC1)c1ccc2n(n1)c(nn2)C1CC1 366.39 1.55 66.64 >25
D-31 Vitas M Labs COc1ccc(cc1)N1CCN(CC1)c1ccc2n(n1)cnn2 310.35 2.13 58.80 >25
D-32 Life Chemicals Clc1ccc(c(c1)NC(=O)N1CCN(CC1)c1ccc2n(n1)cnn2)Cl 392.24 3.01 78.67 ~24.81
D-33 Life Chemicals CCOc1ccccc1NC(=O)N1CCN(CC1)c1ccc2n(n1)cnn2 367.41 2.11 87.90 >25
D-34 Life Chemicals COc1ccc(cc1NC(=O)N1CCN(CC1)c1ccc2n(n1)cnn2)C 367.41 2.16 87.90 >25
D-35 Life Chemicals COc1cc(cc(c1)OC)NC(=O)N1CCN(CC1)c1ccc2n(n1)cnn2 383.40 1.76 97.13 >25
D-36 Life Chemicals O=C(N1CCN(CC1)c1ccc2n(n1)cnn2)Nc1ccc(cc1)C(C)C 365.43 3.23 78.67 >25
D-37 Life Chemicals Fc1ccc(c(c1)NC(=O)N1CCN(CC1)c1ccc2n(n1)cnn2)F 359.33 1.98 78.67 >25
D-38 Life Chemicals O=C(N1CCN(CC1)c1ccc2n(n1)cnn2)Nc1ccc(c(c1)Cl)F 375.79 2.49 78.67 12 (11-14)
D-40 Life Chemicals COc1ccc(cc1NC(=O)N1CCN(CC1)c1ccc2n(n1)cnn2)OC 383.40 1.76 97.13 >25
D-41 Life Chemicals Clc1cccc(c1)OCC(=O)N1CCN(CC1)c1ccc2n(n1)cnn2 372.81 2.03 75.87 18 (16-21)
D-42 Life Chemicals O=C(N1CCN(CC1)c1ccc2n(n1)cnn2)Cc1ccccc1Cl 356.81 2.13 66.64 >25
D-43 Life Chemicals O=C(N1CCN(CC1)c1ccc2n(n1)c(nn2)C1CC1)Nc1ccc(c(c1)Cl)F 415.85 2.94 78.67 >25
D-44 Life Chemicals O=C(c1ccc(cc1)S(=O)(=O)N(C)C)N1CCN(CC1)c1ccc2n(n1)cnn2 415.47 0.25 104.02 7.1 (5.9-8.5)
D-45 Life Chemicals O=C(c1ccc(cc1)S(=O)(=O)N)N1CCN(CC1)c1ccc2n(n1)cnn2 387.42 -0.37 126.80 >25
D-46 Life Chemicals Clc1ccc(cc1)C(=O)N1CCN(CC1)c1ccc2n(n1)cnn2 342.78 1.61 66.64 >25
D-47 Life Chemicals Clc1ccc(c(c1)C(=O)N1CCN(CC1)c1ccc2n(n1)cnn2)Cl 377.23 2.22 66.64 >25
D-48 Life Chemicals O=C(c1ccc(cc1)S(=O)(=O)N1CCCC1)N1CCN(CC1)c1ccc2n(n1)cnn2 441.51 0.65 104.02 >25
D-49 Life Chemicals O=C(N1CCN(CC1)c1ccc2n(n1)cnn2)Cc1noc2c1cccc2 363.37 1.53 92.67 >25
D-50 Life Chemicals Clc1ccc(c(c1)Cl)OCC(=O)N1CCN(CC1)c1ccc2n(n1)cnn2 407.25 2.66 75.87 16 (14-18)
D-51 Life Chemicals Clc1ccc(c(c1)Cl)OC(C(=O)N1CCN(CC1)c1ccc2n(n1)cnn2)C 421.28 3.02 78.87 >25
D-53 Life Chemicals N1CCN(CC1)c1ccc2n(n1)cnn2 204.23 -0.22 58.36 >25
D-60 Vitas M Labs O=C(N1CCN(CC1)c1ccc2n(n1)c(C)nn2)OC(C)(C)C 318.37 1.50 75.87 >25
D-74 Sigma O=C(Nc1ccc(Cl)c(Cl)c1)N2CCN(CC2)c3ccccc3 350.25 4.56 35.57 20 (12-32)
D-75 Life Chemicals FC(F)(F)c1ccc(cc1)NC(=O)N2CCN(CC2)c3ccc4nncn4n3 391.36 2.62 78.67 11 (9.3-13)
D-76 Life Chemicals FC(F)(F)Oc1ccc(cc1)NC(=O)N2CCN(CC2)c3ccc4nncn4n3 407.36 2.69 87.90 >25
D-77 Life Chemicals Clc1cccc(c1)NC(=O)N2CCN(CC2)c3ccc4nncn4n3 357.81 2.38 78.67 ~23.67
D-78 Life Chemicals O=C(N1CCN(C2=NN3C(C=C2)=NN=C3)CC1)NC5=CC=C(Cl)C=C5 357.80 2.40 78.67 >25
D-79 Life Chemicals O=S(N1CCN(C2=NN3C(C=C2)=NN=C3)CC1)(C4=CC=C(OC5=CC=CC=C5)C=C4)=O 436.50 3.04 92.94 12 (9.2-16)
D-80 Life Chemicals O=C(N1CCN(C2=NC3=C(C=CC=C3)N2)CC1)NC4=CC=C(Cl)C(Cl)=C4 390.27 4.38 64.26 17 (14-20)




, calculated using molinspiration property engine versions v2013.09, v2014.11, and v2016.10
c
 EC50, indicates half maximal effective concentration  
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3.1.  Abstract 
Cryptosporidiosis, is a diarrheal disease due to intestinal infection with one of 
several Cryptosporidium species.  It is a leading cause of life-threatening diarrhea in 
young children and causes prolonged disease in malnourished children and 
immunocompromised people like AIDS patients.  Nitazoxanide, the only approved 
drug, is not very effective in these populations.  Large-scale phenotypic screens are 
ongoing to identify anti-Cryptosporidium growth inhibitors (hits).  In the absence of a 
gold standard drug, the in vitro and in vivo properties to guide prioritization of hits are 
not known.  With a goal to prioritize a diverse set of hits without knowledge about the 
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actual mechanism of action, we developed a range of medium-throughput life stage 
assays, including an assay for asexual to sexual conversion that can be used to quickly 
screen a large number of the phenotypic hits.  Fifty-five hits and leads from several 
collaborators in the Bill and Melinda Gates’ Foundations’ Cryptosporidium Consortium 
were tested in all these assays and data was used to cluster compounds.  The 
compounds segregated into seven different clusters with related chemical classes and 
compounds with similar mechanism action grouping together.  Furthermore, 
compounds from different clusters were active in the chronic NOD SCID gamma 
mouse model of cryptosporidiosis, suggesting the assays could be used to obtain and 
maintain diversity in Cryptosporidium drug development pipeline. 
 
3.2.  Introduction 
Diarrhea still causes ~8% of all deaths globally in children under five years of 
age (Disease, Injury, & Prevalence, 2016).   Amongst infectious etiologies, 
cryptosporidiosis recently garnered increased interest when the Global Enteric 
Multicenter Study (GEMS) reported it as a leading cause of life-threatening childhood 
diarrhea in Africa and the Indian subcontinent (Kotloff et al., 2013; Liu et al., 2016).  
Cryptosporidiosis was also strongly associated with malnutrition and mortality.  
Infection of the intestinal epithelium by apicomplexan Cryptosporidium parasites 
causes cryptosporidiosis, and, although over twenty species of Cryptosporidium have 
been reported, Cryptosporidium parvum and Cryptosporidium hominis account for 
almost all human cases (Checkley et al., 2015).  Despite numerous earlier studies that 
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suggested the importance of Cryptosporidium parasites in young children (Shirley, 
Moonah, & Kotloff, 2012), cryptosporidiosis was previously known best as a cause of 
prolonged diarrhea in immunocompromised people, especially AIDS patients in whom 
it is reported to cause as much as 50% of cases (Malebranche et al., 1983; Navin et al., 
1999).  Unfortunately, treatment options for cryptosporidiosis are very limited 
(Checkley et al., 2015).  The only approved drug, nitazoxanide, is equivalent to a 
placebo in AIDS patients (Abubakar, Aliyu, Arumugam, Hunter, & Usman, 2007).  
And its efficacy in young children is modest, with improvement after one week of 
treatment in just over half of children studied compared to spontaneous improvement of 
approximately one quarter of untreated children (Amadi et al., 2009).  Thus, there is a 
clear public health need for improved drugs to treat children and immunocompromised 
people with cryptosporidiosis. 
Given that there is no highly effective treatment for cryptosporidiosis in the 
most affected populations, it follows that there is no well-validated developmental 
pathway for anti-Cryptosporidium drugs (Huston et al., 2015; Manjunatha, Chao, 
Leong, & Diagana, 2016).  Ideally, early-stage investments should be made in 
compounds with a diverse set of molecular mechanisms, since there is currently no 
means to judge which will succeed and which will fail (Katsuno et al., 2015).  The 
situation is further complicated by both economic and technical issues.  First, the 
potential market for anti-Cryptosporidium drugs is small, since the disease 
predominantly affects people in low and middle income countries.  Second, despite 
successful use of CRISPR/Cas9 for genome manipulation, genetic studies must 
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presently be carried out in a mouse, which limits the ability to validate potential drug 
targets (Pawlowic, Vinayak, Sateriale, Brooks, & Striepen, 2017; Vinayak et al., 2015).  
These financial and technical limitations generally favor phenotypic screening 
approaches to identify potential starting points for drug development, since cell-based 
methods typically result in a shorter time to market (i.e. reduced cost of development) 
and do not restrict potential chemical starting points to those that affect a small number 
of previously validated drug targets (Nwaka & Hudson, 2006).  Accordingly, several 
phenotypic cell-based screening methods have now been used successfully to identify 
Cryptosporidium growth inhibitors, and there is a growing number of compounds in the 
developmental pipeline (Bessoff, Sateriale, Lee, & Huston, 2013; Bessoff et al., 2014; 
Chao et al., 2018; Love et al., 2017).  However, without drug target identification, 
which is difficult even in the most developed experimental systems, the current 
approach forfeits the many advantages of target-based drug development for 
compounds for which knowledge from other systems provides no likely mechanism of 
action.  One key disadvantage of a developmental pipeline that is wholly dependent on 
cell-based screening for a single phenotype, is that there is no means to ensure that the 
chemical starting points in development work by a variety of molecular mechanisms. 
In this study, we hypothesized that additional phenotypic assays might provide a 
means to group compounds that correlates with molecular mechanism, even if the 
molecular mechanism of a class of compounds is not known.  Such a collection of 
assays with adequate throughput to be applied to a large number of in vitro inhibitors 
would provide important information for prioritizing early-stage inhibitors by aiding in 
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maintenance of a diverse portfolio of compounds in the pipeline.  The Medicines for 
Malaria Venture (MMV) employs a similar approach for maintenance of the malaria 
drug pipeline (Burrows et al., 2017).  Here, we present new moderate-throughput 
assays assessing compound effects on different life-cycle stages in a C. parvum tissue 
culture infection model, including assays for host cell invasion, intracellular DNA 
replication, parasite egress and reinvasion, and sexual differentiation.  The methods 
were employed on a diverse set of compounds, and using the results from this panel of 
assays, we show that compounds are accurately clustered into different chemical and/or 
mechanistic groups.  These data confirm that the approach enables maintenance of 
mechanistic diversity within the Cryptosporidium drug development portfolio.  We also 
show that compounds targeting different life-cycle stages are active in a highly 
immunocompromised mouse model, which further supports the value of a diverse 
portfolio. 
 
3.3.  Results 
Our overall strategy to determine if life-stage specific phenotypic assays enable 
classification of compounds according to chemical class/mechanism of action was to 
develop a panel of suitable assays and then use them to test a panel of “learning” 
compounds, which enabled subsequent clustering of compounds based on phenotype.  
The learning compounds used were from a variety of sources.  For assay development 
and initial validation, publically available drug screening hits and anti-Cryptosporidium 
compounds disclosed in the literature were tested (e.g. from the Medicines for Malaria 
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Venture Open Access Box and the National Institutes of Health (NIH) Clinical 
Collection) (Bessoff et al., 2013; Bessoff et al., 2014; Jumani et al., 2018).  To 
subsequently enlarge the database and determine if grouping compounds according to 
phenotype results in segregation of compounds by chemical class and/or mechanism of 
action, we also utilized proprietary compounds provided by collaborators within the 
Bill and Melinda Gates Foundation Cryptosporidium Drug Accelerator consortium.  In 
most cases, these compounds were identified as C. parvum inhibitors by screening 
libraries of compounds partially developed for other indications (e.g. treatment of 
malaria, trypanosomiasis, tuberculosis, etc.), and many of these compounds had the 
advantage for purposes of our study that their likely molecular mechanisms of action 
are known (Castellanos-Gonzalez et al., 2013; Gorla et al., 2012; Jain et al., 2017; Kato 
et al., 2016; Love et al., 2017; Shibata et al., 2011). 
As a first step in developing specific Cryptosporidium life-stage assays, we 
conducted a series of light microscopy time-lapse and transmission electron microscopy 
(TEM) timecourse experiments in order to precisely define C. parvum development in 
our hands in the HCT-8 cell culture system.  Consistent with previously published 
studies, all life-cycle stages were observed, including development of type II meronts, 
macro- and micro-gametocytes, and rarely, even fertilization (Fig. 1).  Although 
Cryptosporidium parasites in the HCT-8 cell culture system were not fully 
synchronized, initial excystation and cell invasion occured within an ~2.5 hour 
window, resulting in a roughly synchronized infection.  This knowledge was exploited 
to modify a previously developed high-content microscopy assay to focus on major 
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life-stage events observed in the HCT-8 culture system; assays for host cell invasion, 
intracellular replication, host cell egress and establishment of new parasitophorous 
vacuoles, and sexual differentiation were developed (see light microscopy images or 
transmission electron micrographs (TEMs) in each assay figure) with the goal of 
enabling classification of multiple compounds to assist with drug development. 
 
3.3.1.  Host cell invasion assay 
The first step in infection is host cell invasion and involves a complex 
phenotype encompassing oocyst excystation, parasite motility, adhesion, and ultimately 
parasitophorous vacuole formation (Fig. 2A).  Our strategy to assay for invasion 
inhibitors was simply to expose C. parvum to compounds immediately after triggering 
excystation and throughout the invasion process, but with enumeration prior to 
allowing intracellular parasites to replicate (summarized in Fig. 2B).  The resultant 
assay method was the same as a high-content microscopy assay method for C. parvum 
development that we published previously (Bessoff et al., 2013), except for the time 
points of compound addition and monolayer fixation.  Like the prior method, this 
method has medium-throughput, and it has a Z’ score of ≥ 0.2. 
Neural Wiskott Aldrich syndrome protein (N-WASP) and Cdc42 pathway are 
important for the initial host cell actin remodeling required for Cryptosporidium 
parasitophorous vacuole formation (Chen et al., 2004), and the small molecule 
wiskostatin has been shown to inhibit purified N-WASP at 10 µM, including 
competitive inhibition of its activation by Cdc42 (Peterson et al., 2004).  Therefore, 
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wiskostatin was used as a positive control for initial assay validation and optimization 
of the C. parvum invasion assay.  Wiskostatin was active in the 48 hour C. parvum 
development assay with a 90% effective concentration (EC90) of 11.3 µM.  Wiskostatin 
also inhibited parasitophorous vacuole formation at this EC90 concentration, giving 
results similar to those obtained using heat-killed oocysts or fixed HCT-8 cells (Fig. 2C 
and 2D).  As further proof-of-concept, confirmed C. parvum inhibitors from the MMV 
Malaria Box and commercially available chemical analogues of each (Supplementary 
Table 1) were tested at the EC90 concentration measured previously for each using the 
48 hour C. parvum development assay (Fig. 2D).  The anti-C. parvum 2,4-
diaminoquinazolines inhibited host cell invasion, while allopurinol-, quinolinol-, and 
piperazine-based anti-C. parvum compounds had no effect on parasitophorous vacuole 
formation.  The approved drug nitazoxanide and paromomycin, which is often used as a 
positive control in Cryptosporidium mouse models, also had no significant effect (Fig. 
2D).   
 
3.3.2.  DNA replication assay 
Following cell invasion, Cryptosporidium trophozoites grow and multiply to 
give rise to multinucleated type I meronts (Fig. 3A).  The thymidine analog 5-ethynyl-
2´-deoxyuridine (EdU) is efficiently incorporated into newly synthesized DNA, and can 
be readily detected using click chemistry (Salic & Mitchison, 2008).  We therefore used 
EdU to measure parasite intracellular DNA synthesis, which is a surrogate for the more 
complex phenotype of intracellular growth and division.  The approach for 
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differentially labeling newly synthesized parasite DNA compared to host cell DNA was 
to take advantage of the fact that C. parvum replicates more quickly than the nearly 
confluent host cells.  Thus, by adding EdU for a short time period shortly before egress, 
it was possible to preferentially label replicating parasites (Fig. 3B and C).  In contrast, 
DNA staining with Hoechst labelled all of the host and parasite DNA, making it 
challenging to visualize and quantify parasite DNA due to excessive host DNA.  A 
simple DNA stain would also not distinguish pre-existing DNA from newly synthesized 
DNA (Fig. 3C).  In contrast, EdU labeling only occurs with incorporation into newly 
synthesized DNA.  Incorporated EdU was then easily stained for immunofluorescence 
and labeled parasites were quantified using high-content microscopy and an NIH 
ImageJ macro (Fig. 3C, DMSO condition).  The thymidine analogue hydroxyurea (10 
mM), a known inhibitor of DNA replication, was used as a positive control for assay 
validation.  As expected, hydroxyurea at this concentration blocked both parasite and 
HCT-8 cell DNA replication (Fig. 3C).  The MMV Malaria Box quinolinol series, 
compounds previously identified as selective C. parvum inhibitors, appeared to 
selectively block C. parvum replication (Fig. 3C and D).  The 2,4-diaminoquinazolines 
(parent MMV006169), which all inhibited host cell invasion, had no effect on 
intracellular replication.  Results for the other compounds tested were also consistent 
within chemical groups:  the allopurinol-based chemical scaffold MMV403679 blocked 
C. parvum replication, while the piperazine-based scaffold (MMV665917) and 
paromomycin had no effect on EdU incorporation (Fig. 3D).   As noted above, 
compounds with activity in this assay cannot be concluded to be DNA synthesis 
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inhibitors; rather, they affect at least one of the many things that DNA synthesis 
requires.  Also, as is evident from the images, it would be feasible to enumerate the 
number of nuclei present in each vacuole to obtain subtler information; however, for 
the purpose of classifying compounds, we found that a readout based simply on C. 
parvum EdU counts normalized to total parasite numbers was readily automated using 
NIH ImageJ and worked well (Fig. 3D).  
 
3.3.3.  Parasite egress and host cell reinvasion assay 
Type I meronts release motile merozoites that infect new HCT-8 cells and 
repeat the asexual replication cycle.  We performed live microscopy on infected cells to 
visualize and better understand these processes in the in vitro assay system.  There was 
modest experiment-to-experiment variation in the timing of events, with egress 
sometimes beginning as early as 12 h post infection and observed as late as 18 h post 
infection; within each experiment, the cultures were more synchronized with all egress 
occurring within an ~ 2.5 h time window.  Individual C. parvum egress and reinvasion 
events were rapid, with parasitophorous vacuole rupture, merozoite release and re-
attachment completed within 10 minutes.  Re-infection was inefficient, and each 
parasitophorous vacuole egress event only produced ~ 2-3 new vacuoles (Fig. 4A, and 
Supplementary Video 1). 
To identify a suitable positive control compound to aid in development of a 
quantitative assay, we reasoned that compounds active in the DNA replication assay 
would also inhibit this subsequent stage of parasite development.  Thus, we used time-
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lapse light microscopy to assess inhibition of cell egress by the allopurinol-based 
scaffold MMV403679 (C-1), which was active in the DNA replication assay.  As 
anticipated, C-1 at the 2 × EC90 (1.3 µM total) inhibited parasite egress during live 
microscopy (Fig. 4B, and Supplementary Videos 2 and 3).  Furthermore, based on the 
time-lapse observations, it was clear that in this crudely synchronized culture system 
parasite vacuole numbers did not increase smoothly; rather, vacuole numbers increased 
by ratcheting up by two to three-fold during the window of egress and infection of new 
host cells.  This observation was confirmed by comparing parasite numbers in the 
presence of C-1 vs. the vehicle control at time points approaching and just following 
the approximate time of cell egress and reinvasion (Fig. 4C). 
This observation suggested a less labor intensive method to estimate the effect 
of compounds on parasite egress and establishment of new parasitophorous vacuoles 
simply by measuring the ratio of the number of parasite vacuoles following and before 
the egress/reinvasion life-cycle stage (Fig. 4D).  Time points of 19.5 h post-infection 
and 6 h post-infection were selected empirically.  As seen in the timecourse experiment 
with the DMSO vehicle, the ratio of parasites at 19.5 hours to parasites at 6 hours 
ranged from 2.5 to 3-fold (Fig. 4C and 4E).  Compounds acting at all stages up to and 
including parasite egress and reinvasion would be expected to reduce this ratio; 
furthermore, rapidly cidal compounds that act early, or compounds that permit egress 
but block subsequent reinvasion would result in a ratio below 1. 
Given the complexity of this phenotype and the need to interpret the results in 
the context of the results of assays of earlier life-stages, it is not surprising that the 
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learner compounds tested resulted in a range of ratios.  Wiskostatin, which here was 
added at three hours post-infection, following the invasion step, resulted in a ratio of 
almost precisely one.  The allopurinol-based and quinolinol compounds consistently 
displayed ratios that were reduced but under 1, whereas the piperazines, 2,4-
diaminoquinazolines, nitazoxanide and paromomycin all displayed ratios above 1.  As 
with the other assays, the results were similar for all compounds within each chemical 
group.  And, as expected, compounds acting at earlier stages showed at least some 
reduction in the ratio of vacuoles at 19.5 hours to vacuoles at 6 hours (Fig. 4E and 
Supplemental Table 2).  This was especially evident for compounds such as the 
quinolinols and allopurinol-based compounds that blocked intracellular development, 
and likely occurred simply because no merozoites matured for egress. 
 
3.3.4.  Sexual differentiation assay 
Unlike malaria parasites for which only a small fraction of blood stage parasites 
undergo sexual differentiation, Cryptosporidium is believed to undergo sexual 
differentiation in an obligate manner after only three to four rounds of asexual 
replication.  Furthermore, a single host serves as the site of both asexual and sexual 
reproduction (i.e. is both the intermediate and definitive host) (Current & Reese, 1986).  
Therefore, although all of the early-stage drug leads studied to date for 
cryptosporidiosis were identified using assays that measure only effects on asexual 
development, it is theoretically possible to target sexual development for treatment of 
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cryptosporidiosis.  Based on this logic, we sought a method to quantify C. parvum 
sexual differentiation. 
 
3.3.4.1.  Identification of DMC1 (cgd7_1690) as a marker for sexual stages   
Based on the accepted Cryptosporidium life-cycle, C. parvum is haploid at all 
stages except for just after fertilization, at which time the diploid zygote quickly 
undergoes meiosis to give rise to haploid spores within thick and thin-walled oocysts 
that are either passed in the feces or excyst to perpetuate the infection (Current & 
Reese, 1986).  Since meiosis only occurs following fertilization, we reasoned that genes 
encoding proteins specifically involved in meiosis might only be expressed in sexual 
forms of the parasite, including either the zygote or gamonts.  Using gene expression 
data publically available via CryptoDB (http://cryptodb.org) (Mauzy, Enomoto, Lancto, 
Abrahamsen, & Rutherford, 2012), we selected the DNA Meiotic Recombinase 1 gene, 
DMC1 (cgd7_1690), as a likely candidate for use as a C. parvum sexual stage marker, 
since this gene increases in expression dramatically following ~48 of culture in HCT-8 
cells and is also specific to Plasmodium sexual differentiation (Mlambo, Coppens, & 
Kumar, 2012).  The predicted C. parvum DMC1 protein sequence is 99% identical to 
the predicted orthologous C. hominis (Chro.70199) protein, and the C. parvum protein 






3.3.4.2.  Validation of DMC1 in vitro 
Real-time PCR (qRT-PCR) and transmission electron microscopy (TEM) were 
used to determine if DMC1 expression correlated with the appearance of sexual-stage 
parasites in the HCT-8 culture system.  To avoid slight variations in growth kinetics 
that occur between experiments, samples from neighboring wells of the same infection 
were analyzed, focusing on finer time-points around 48 h post-infection when gamonts 
were first expected to appear.  DMC1 expression was first detected at 42 h post-
infection, simultaneously with the first appearance of gamonts seen by TEM (Fig 5A 
and 5B).  DMC1 mRNA levels increased by > 100-fold between 36 hours and 72 hours 
of culture, and DMC1 mRNA was not detected in sporozoites or oocysts.  Interestingly, 
DMC1 expression decreased after peaking at 72 h post-infection. 
An anti-C. parvum DMC1 mouse monoclonal antibody was produced in order 
to determine if DMC1 protein expression also correlated with the life-stages present in 
culture, and to generate a potential reagent to assay C. parvum sexual development by 
high-content immunofluorescence microscopy.  A clear subset of parasite vacuoles 
stained positive for DMC1 at 72 hours post-infection, confirming the specificity of the 
reagent (Fig. 5C).  DMC1 was detected exclusively in vacuoles that were not multi-
nucleated, suggesting that it may be specifically expressed in macrogametocytes and/or 
fertilized zygotes.  Immunogold staining and TEM with the anti-DMC1 antibody was 
unsuccessful, however, so the specific life-stage stained could not be determined with 
certainty.  The timing of protein expression was similar to that of mRNA expression, 
with DMC1 positive parasites first detected at 42 h post-infection, peaking at 72 h post-
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infection and then decreasing in number (Fig 5D).  At peak expression levels, ~55 % of 
the lectin-positive parasites expressed DMC1. 
 
3.3.4.3.  Assay to identify inhibitors of asexual to sexual stage conversion 
Based on the results above, we utilized DMC1 as a marker of C. parvum sexual 
development, and used the anti-DMC1 monoclonal antibody to develop a moderate-
throughput high-content microscopy assay for characterizing anti-Cryptosporidium 
compounds (Fig. 6A).  Since the percent of DMC1 positive parasites began to increase 
just prior to 48 hours after infection in the HCT-8 cell system, the strategy was to test 
the specific effect of compounds on sexual development simply by delaying addition of 
compounds until 48 hours post-infection and then monitoring the effect on the number 
of DMC1 positive parasites at 72 hours.  Compounds with equal efficacy on the asexual 
and sexual stages would be expected to have equal potency both before and after 48 
hours.  The piperazine-based compound D1 (MMV665917) was such a compound (Fig. 
6B).  On the other hand, the 2,4-diaminoquinazoline B1 (MMV006169) was far less 
potent when used during the sexual phases of development (Fig. 6B), suggesting that it 
is relatively specific for asexual development.  In practice, many compounds gave an 
intermediate phenotype with partial inhibition of DMC1 expression when added at 48 
hours.  Therefore, in order to enable numerical comparison of the ability of compounds 
to block sexual development with moderate throughput, we adopted a strategy of 
reporting the percent inhibition of DMC1 expression by the previously determined EC90 
in the standard/asexual development assay (Fig. 6C and Supplementary Table 3). 
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3.3.5.  Identification of hit diversity based on life-stage activity 
A major goal of our study was to determine if compounds could be grouped by 
chemical class/mechanism of action using these phenotypic assays, in which case they 
could be used to maintain mechanistic diversity in the Cryptosporidium drug 
development pipeline even in the absence of knowledge of the molecular mechanisms 
of phenotypic screening hits.  To test this idea, the panel of phenotypic assays described 
above was used to characterize a panel of fifty-five compounds, and the data were 
analyzed using a clustering algorithm based on the Ward error of sum of squares 
hierarchical clustering method with a distance matrix generated using Euclidean 
distances calculated for each compound with respect to another.  Specific phenotypic 
assay data for each compound are given in Supplementary Table 3.  The method 
separated the compounds into distinct clusters, grouping compounds based on the same 
chemical scaffold (i.e. presumed to have the same molecular MOA) and compounds 
known to work via the same/highly similar MOAs (e.g. compounds effecting a variety 
of tRNA-sythetases) (Fig. 7). 
 
3.3.6.  Correlation between in vitro assay activity and in vivo efficacy 
It is feasible that Cryptosporidium is most susceptible to drug treatments that 
target a specific life cycle stage (e.g. the relatively prolonged intracellular growth and 
replication stage).  Therefore, for the strategy of ensuring mechanistic diversity in the 
Cryptosporidium drug development pipeline based on activity against different life 
cycle stages, it was critical to determine if compounds belonging to different 
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phenotypic clusters (as in Fig. 7) could have in vivo efficacy.  For this, a variety of 
compounds were tested in a mouse model of chronic C. parvum infection. 
The factors that drive compound efficacy in a mouse model of cryptosporidiosis 
are not known.  This is particularly complicated by the fact that, although drugs are 
obviously needed at the intestinal site of the infection, the precise pharmacokinetic 
properties desired for an effective drug are not certain and might vary based on the 
mechanism of action of different drugs.  Furthermore, different animal models with 
varying stringency (e.g. self-resolving vs. chronic infection models) have been used for 
lead identification (Castellanos-Gonzalez et al., 2013; Gorla et al., 2014; Jumani et al., 
2018; Love et al., 2017; Manjunatha et al., 2017; Ndao et al., 2013).  To directly 
compare in vivo efficacy of compounds, we tested most of these compounds in the 
highly immunocompromised NOD SCID gamma (NSG) mouse model of established C. 
parvum infection.  The in vitro and in vivo data provide a rich source to identify 
correlations between in vitro activity in these assays and in vivo efficacy in the NSG 
mouse model.  Along with the above life cycle assays, we also tested all of the 
compounds in the previously reported in vitro parasite persistence assay to determine 
rate of parasite elimination in vitro (Jumani et al., 2018).  While screening a larger 
number of compounds, we found the earlier definition of static versus cidal too 
simplistic.  Compounds behaving like nitazoxanide were still classified as static, 
whereas compounds with an fast rate of parasite decay like in the case of MMV665917 
were categorized as exponential inhibitors and compounds with a slow rate of parasite 
elimination similar to paromomycin were categorized as linear inhibitors 
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(Supplementary Table 3).  There was no specific asexual stage assay that alone 
correlated with in vivo efficacy, and all of the compounds with in vivo activity had at 
least a partial activity in the asexual to sexual conversion assay.  None of the static 
compounds were active in the NSG mouse model (Supplementary Table 3).  
 
3.4.  Discussion 
We report a range of inexpensive medium-throughput C. parvum life stage 
assays that can be used to classify compounds quickly and obtain a diverse set, which 
can aid in prioritization of hits and leads for further drug development.  We found a 
good correlation between variants within a chemical series, and for compounds with 
several putative mechanisms of action, including ATG-8 inhibitors, CDPK-1 inhibitors, 
and four different classes of tRNA synthetase inhibitors.  And importantly, compounds 
belonging to numerous mechanistic clusters were effective in the NSG mouse model. 
Currently, large-scale phenotypic screening efforts are ongoing to identify hits 
against Cryptosporidium (Chao et al., 2018; Love et al., 2017).  There are no 
established methods to help prioritize these hits.  In malaria drug development, stage 
specific assays have been used for prioritization of compounds, with distinct target 
candidate profiles based on rate of parasite elimination and stage specific activity 
(Burrows et al., 2017; Burrows, van Huijsduijnen, Mohrle, Oeuvray, & Wells, 2013; 
Delves et al., 2012).  This strategy helps maintain diversity in the pipeline drug 
development pipeline and increases the chances of delivering quality preclinical 
candidates.  This is particularly important in the case of malaria where drug resistance 
105 
 
is a major issue.  We have already reported an in vitro parasite persistence assay to 
determine the rate of C. parvum elimination following compound exposure (Jumani et 
al., 2018).  We believe these specific life stage assays are a quick, relatively 
inexpensive way to prioritize anti-Cryptosporidium hits in a manner similar to that used 
for malaria drug development.  Genetic studies can then be done on a smaller set of 
promising leads to identify the targets (Pawlowic et al., 2017). 
The set of 55 compounds used here is relatively small to draw correlations 
between in vitro assays and in vivo efficacy, especially without considering the PK 
properties of the compounds.  However, this is the first report of directly comparing in 
vivo efficacy with in vitro assays for such a large number of anti-Cryptosporidium hits.  
These data can be used to understand factors critical for in vivo efficacy in the absence 
of an effective benchmark drug.  These correlations can be better understood with an 
increase in the number of compounds, and with human and calf model clinical efficacy 
data.  Apart from the life stage assays, pharmacodynamic parasite persistence assay and 
PK considerations, several other factors like an effect on microbiome could drive in 
vivo efficacy and should be measured (Gorla et al., 2014).  These assays are not an 
exhaustive list, but rather should be used as a starting point. 
To directly compare all compounds irrespective of potency, the EC90 
concentration from our standard asexual inhibition assay was used in all life stage 
assays.  A single EC90 concentration was chosen to determine the predominant effect of 
the compound on parasite life stage with a goal to directly compare compounds to 
attain diversity in a relatively quick and inexpensive manner using small quantities of 
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compounds.  It is possible that at higher concentrations, compounds would be active 
against more than one stage.  For compounds of high interest, it may be worth 
following up with dose response curves for all life stage assays. 
With the idea to develop a medium-throughput assay along with the technical 
difficulties involved, the invasion assay protocol exposes sporozoites directly to 
compounds for a fleeting time.  The design of the assay makes it easier to identify 
compounds that inhibit invasion by acting on host cells and this should be kept in mind 
when interpreting this assay’s results.  Interestingly, none of the compounds active in 
the invasion assay were efficacious in the NSG mouse model.  This could be due to a 
small sample size of compounds tested and should not be interpreted as evidence that 
invasion inhibitors are inactive in vivo against cryptosporidiosis. 
Compounds with activity against any process post-invasion and not just 
replication inhibitors are expected to be active in the DNA synthesis assay.  Hence, one 
potential reason that all the aminoacyl tRNA synthetase inhibitors were potent in this 
assay could be that they are all lethal to the parasite before it incorporates EdU.  N-
WASP and host actin re-modeling are important for intracellular Cryptosporidium, in 
addition to their role in host cell invasion  (Elliott et al., 2001).  It is not surprising, 
therefore, that wiskostatin was active in both the DNA synthesis assay and the invasion 
assay. 
Interestingly, all compounds had some activity, but to varying extents in the 
egress, merozoite motility and reinvasion assay.  A ratio of less than one would signify 
disintegration of existing vacuoles without egress and/or egress without formation of 
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new vacuoles.  The 2,4-diaminoquinazolines were potent sporozoite invasion inhibitors 
but had a ratio of greater than 1, suggesting that they do not affect merozoite invasion 
as efficiently.  Using the parasitophorous vacuole number ratio was useful to classify 
compounds based in a higher throughput manner.  Nonetheless, these data can be used 
to further investigate specific mechanisms.  For example, a sub-set of compounds could 
be used in the live egress assay set-up to identify if egress or merozoite release, motility 
or reinvasion is specifically affected. 
We have shown that in vitro C. parvum DMC1 mRNA and protein expression 
coincides with appearance of sexual gamont stages in HCT-8 cells.  Although a strong 
correlation between appearance of gamonts and DMC1 has been demonstrated, it is 
only correlative.  Since immunogold staining with this antibody failed, and there are no 
other tools to label C. parvum gamonts, we cannot determine the specific parasitic stage 
wherein DMC1 appears.  Our data show that at 72 h, when 80 % of the parasites were 
gamonts by TEM, ~55 % of parasites were DMC1 positive by immunofluorescence.  
Added on, DMC1 is not expressed in multinucleated cells.  Microgamonts are 
multinucleated due to multiple microgametes per vacuole.  Assuming microgamont 
nuclei get stained with Hoechst, DMC1 is not expressed in microgamonts, leaving the 
only possibility being fertilized or non-fertilized macrogamonts.  The fertilization of a 
macrogamont is considered a rapid process, as only the macrogamonts or early oocysts 
can be predominantly imaged by TEM with an intermediate containing a 
distinguishable macrogamete nucleus very rarely seen.  Hence, the C. parvum DMC1 
could be expressed in a fertilized or non-fertilized macrogamont.  Given the role of the 
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conserved DMC1 during meiosis in other organisms, it is possible that DMC1 
expression comes up after fertilization and fusion of the macrogamete nucleus with the 
macrogamont nucleus, making DMC1 a marker for fertilization.  On the other hand, 
DMC1 could be pre-expressed in macrogamonts to facilitate rapid fertilization and 
oocyst formation, giving the parasite an advantage for rapid turnover and re-infection.  
Either way, these raise very interesting possibilities about the biology of 
Cryptosporidium.  The identification of DMC1 as a marker for the appearance of 
gamonts makes it more feasible to explore the sexual stage biology of Cryptosporidium.  
Until now there has only been a screening assay to predominantly look at asexual stage 
inhibitors, but with the DMC1 antibody a high-throughput screening assay can be 
developed for the first time to identify potential sexual stage inhibitors.  Apart from 
drug candidates, the results can potentially yield invaluable tool compounds to explore 
Cryptosporidium biology. 
This is a first report of dose response curves against asexual to sexual stage 
conversion.  It was interesting to find compounds with similar potency against the 
asexual stages and DMC1 assay.  Partial inhibitors are more difficult to interpret, as the 
C. parvum in vitro growth assay is a mixed and asynchronized culture with a 
combination of asexual and sexual stages present.  The DMC1 assay was designed such 
that compounds were added after about 20% gamonts were already formed.  Therefore, 
compounds with pan activity against both stages are expected to completely inhibit 
DMC1, whereas fast acting compounds with activity against asexual stage parasites still 
present at 48 h might appear to partially affect sexual development.  Furthermore, it is 
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not clear if a drug needs to be active against the asexual and sexual stages of the 
parasite, or if activity against any one stage is sufficient.  It was interesting to note that 
all the compounds that were active in vivo in the NSG mice had some activity in the 
DMC1 assay.  It would be interesting to identify pure inhibitors of sexual development 
and test if they would be active in the NSG mouse model.  
In summary, we report and validate a range of medium-throughput in vitro life 
stage assays, including an asexual to sexual stage conversion assay.  This panel of 
assays can form the basis to directly compare compounds, thereby obtaining diversity 
and aiding prioritization at an early stage of Cryptosporidium drug development. 
 
3.5.  Methods 
3.5.1.  Cell culture and C. parvum excystation and infection 
HCT-8 cells were purchased from ATCC and cultured in ATCC modified 
RPMI-1640 medium (Invitrogen), supplemented with 10% heat-inactivated fetal bovine 
serum (Sigma-Aldrich) and 120 U/mL penicillin and 120 μg/mL streptomycin (ATCC) 
(culture media).  For dose response assays using DMC1, amphotericin B at 0.5 μg/mL 
was included in the culture media.  For all experiments, HCT-8 cells between passages 
9 and 39 were used.  C. parvum oocysts were purchased from Bunchgrass Farms, stored 
at 4°C and used within 5 months of being shed.  Oocyst excystation was performed as 
described previously (Bessoff et al., 2013).  Briefly, oocysts were first treated with 10 
mM hydrochloric acid for 10 min at 37°C, spun at 14000 g for 4:30 min at room 
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temperature, then treated with 2 mM sodium taurocholate for 10 min at 16°C, spun as 
before and resuspended in culture media for infection.  
 
3.5.2.  Invasion assay 
C. parvum invasion inhibition was measured by modifying a previously 
described immunofluorescence assay (Bessoff et al., 2013).  HCT-8 cells at >99% 
confluence in 384-well plates were pre-treated with 2 × EC90 concentration of 
compounds for 1 h before infection with parasites.  In the meantime, Iowa strain 
oocysts were excysted.  To each well, 49500 oocysts triggered for excystation were 
added to HCT-8 cell monolayers containing DMSO or compounds diluted to a final 
concentration of EC90 with the addition of oocysts.  Plates were incubated at 37°C and 
5% CO2 for 3 h.  Wells were then washed 3 times with PBS containing 111 mM D-
galactose (PBS-D-gal), fixed with 4% paraformaldehyde (PFA) in PBS for 15 mins at 
room temperature, permeabilized with 0.25% Triton X-100 for 10 mins at 37°C, 
washed 3 times with PBS with 0.1% Tween 20, and blocked with 4% bovine serum 
albumin (BSA) in PBS for 2 h at 37°C or 4°C overnight.  Parasitophorous vacuoles 
were stained with 1.33 µg/mL of fluorescein-labeled Vicia villosa lectin (Vector 
Laboratories) diluted in 1% BSA in PBS with 0.1% Tween 20 for 1 h at 37°C, followed 
by addition of Hoechst 33258 (Anaspec) at 0.09 mM diluted in water for another 15 
mins at 37°C.  Wells were then washed 5 times with PBS containing 0.1% Tween 20.  
A Nikon Eclipse Ti2000 epifluorescence microscope with an automated stage was 
programmed using NIS-Elements Advanced Research software (Nikon, USA) to focus 
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on the center of each well and take a 3×3 or 6×6 composite image using an EXi blue 
fluorescence microscopy camera (QImaging, Canada) with a 20X objective (NA = 
0.45).  Nuclei and parasite images were separately exported as .tif files and analyzed 
using macros developed on the ImageJ platform (National Institutes of Health) (Bessoff 
et al., 2013).  The only modification from the published macro used to count parasites 
was that the lower size threshold for parasites was decreased from 16.5 to 4 pixel (1 
pixel = 0.65 µm).  The same microscope, camera and softwares were used for all 
immunofluorescence assays. 
 
3.5.3.  DNA synthesis assay 
Glass bottom 96 or 384 well plates were coated with 50 µg/mL fibronectin (BD 
Pharmingen) as per manufacturers protocol.  HCT-8 cells were grown to greater than 
90% confluence in the coated glass bottom plates.  Oocysts at a concentration of 55000 
per well were triggered for excystation and added to cells.  After allowing 3 h for 
invasion, cells were treated with EC90 concentration of compounds for 6 h followed by 
addition of 10 mM 5-ethynyl-2´-deoxyuridine (EdU).  After incubation of cells with 
EdU for 2 h, cells were washed 3 times with PBS-D-gal and then fixed with PBS 
containing 4% PFA.  Cells were then permeabilized and stained for EdU using the 
Click-iT® assay kit (Thermo Fisher Scientific) as per manufacturers indication.  Cells 
were then imaged using a 40X air objective (0.7 NA) and EdU and lectin numbers 




3.5.4.  Time-lapse light microscopy for visualizing live C. parvum egress 
Glass bottom 60 mm MatTek dishes (MatTek) were first coated with 50 µg/mL 
fibronectin (BD Pharmingen) as per manufacturer’s protocol and then HCT-8 cells 
were grown to >95% confluence before infecting each MatTek dish with 48×104 
oocysts that had been triggered for excystation.  Cells were then imaged live with 5 min 
intervals using a DIC phase and a 60X oil objective (1.4 NA).  For effect of compound 
C-1 on egress using live microscopy, 16 well polystyrene dishes (Greiner Bio-One™) 
were similarly coated with 50 µg/mL fibronectin (BD Pharmingen).  HCT-8 cells were 
grown to >95% confluence before infection with 15×104 oocysts triggered for 
excystation.  After 3 h cells were gently washed with warm complete media to remove 
oocysts shells before compound or DMSO addition.  Large 2×2 images were taken live 
with 20 min intervals using a 40X air objective (0.7 NA) to visualize live egress. 
 
3.5.5.  Egress, motility, reinvasion assay 
For quantification of parasitophorous vacuoles for timecourse experiment and 
ratio experiment, HCT-8 cells were grown to greater than 90% confluence in 384 well 
plates and infected with 11000 oocysts after they were triggered for excystation.  
Compounds at EC90 concentration were added to cells 3 h after infection and cells were 
washed, stained and imaged at different time points using the same protocol as 





3.5.6.  C. parvum DMC1 (cgd7_1690) identification 
The predicted protein sequence of Plasmodium berghei DMC1 was obtained 
from PlasmoDB (plasmodb.org), the free online Plasmodium genome database, and a 
protein BLAST against C. parvum genome was perfromed using the default settings in 
the free online Cryptosporidium genome database, CryptoDB (http:cryptodb.org).  
 
3.5.7.  Quantitative Real-time PCR 
HCT-8 cells were seeded into 12 well culture plates (Corning) and grown to 
greater than 90 % confluence.  Oocysts at a concentration of 1.92 × 105 oocysts per 
well were excysted and added to cells.  Infected HCT- 8 cells were then incubated for 
varying lengths of time post-infection until RNA extraction was performed.  
At given time points, infected cells were trypsinized, pelleted and RNA 
extracted as previously described (Hobbs et al., 2014).  Briefly, infected cell pellets 
were homogenized with TRIzol™ (Invitrogen), treated with chloroform, and then RNA 
precipitated with ethanol.  RNA was purified using RNeasy kit (Qiagen) according to 
manufacturer’s protocol, and quantitated using NanoDrop.   Superscript III First-Strand 
Synthesis System for RT-PCR (Invitrogen) was used to convert 730ng of RNA per 
sample into cDNA following the manufacturer’s protocol.  To amplify cDNA samples, 
a BIO-RAD CFX96 real-time PCR machine was used with iTaq™ Universal SYBR® 
Green Supermix (BIO-RAD) following the manufacturer’s protocols including melting 
curve analysis.  Real-time PCR primers were designed for DMC1 (cgd7_1690) using 
IDT’s real-time primer design tool, and the sequences used are as follows: forward 
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sequence- GTTGATGGGCGGATTTGAAAG, reverse sequence- 
AACAGACTTTCCCATTACCTCC.  The expression of the DMC1 (cgd7_1690) gene 
was normalized to C. parvum 18s rRNA using the delta CT method (Rider et al., 2005).  
 
3.5.8.  Transmission electron microscopy 
HCT-8 cells were grown and infected with C. parvum oocysts as mentioned 
above for real-time PCR.  Infected cells were harvested at specific time points using 
trypsin, pelleted and fixed in preparation for electron microscopy as previously 
described, with minor modifications, including substitution of 0.1 M cacodylate buffer 
for millonig phosphate buffer.  In short, pelleted cells were fixed for 1 h at 4°C using 
half-strength Karnovsky’s fixative (1% Paraformaldehyde, 2.5% Glutaraldehyde in 0.1 
M cacodylate buffer (pH 7.2)), embedded in 2 % agarose, crosslinked with 
Karnovsky’s fixative, and post-fixed with 1 % Osmium tetraoxide (Barkhuff et al., 
2011).  Samples were then dehydrated with increasing amounts of ethanol, followed by 
propylene oxide (PO), and then infiltrated gradually from PO into Spurr’s resin, 
embedded and polymerized.  Semi-thin sections (1 mm2) were cut with glass knives on 
a Reichert Ultracut microtome.  Ultra-thin sections (60-80 nm) were cut with a 
diamond knife, retrieved onto 200 mesh copper grids, contrasted with uranyl acetate 
(2% in 50% ethanol) and lead citrate, and examined with a JEM 1400 transmission 





3.5.9.  DMC1 Immunofluorescence microscopy 
Monoclonal antibody production in mice was contracted out to GenScript who 
generated antibodies using recombinant C. parvum DMC1.  Several monoclonal 
antibodies were screend by immunofluorescence microscopy with clone 1H10G7 
giving the best signal.   
Greater than 90 % confluent HCT-8 cells grown in fibronectin coated 60 mm 
glass bottom dishes (MatTek) were infected with excysted oocysts for specified 
amounts of time.  Oocysts at 1e6 oocysts per dish were taken for excystation.  At given 
time points post-infection, infected cells were washed 3 times with PBS containing 111 
mM of D-galactose, fixed for 15 min at room temperature with 4 % paraformaldehyde 
in PBS, and permeabilized with 0.25 % triton X-100 in PBS for 10 min at 37°C.  Cells 
were then washed 3 times with PBS and blocked at least overnight at 4°C with 1 % 
BSA in PBS (block).   Cells were stained with monoclonal antibody (1H10G7), either 
neat culture supernatant or 12.8 µg/mL of purified protein in block for 1 h at 37°C, 
followed by 2 washes with PBS.  Cells were then co-stained with goat anti-mouse 
Alexa fluor 568 (Invitrogen) and 1.33 µg/mL fluorescein labeled Vicia villosa lectin 
(Vector Laboratories) diluted in block for 1 h at 37°C.  Stains were then removed and 
0.09 mM Hoechst 33258 (Anaspec) also diluted in block added for another 15 min at 
37°C, followed by 2 PBS washes and imaging on Nikon Eclipse Ti2000 
epifluorescence microscope run with NIS-Elements Advanced Research software 
(Nikon, USA) and equipped with EXi blue fluorescent microscopy camera (QImaging, 
Canada).  For counting, large 2 × 2 images with 15 % overlap were taken using a 40X 
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air objective (0.7 NA), and for finer details Z stack images taken using a 60X oil 
objective (1.4 NA).  Lectin positive cells in focus were first counted, followed by 
DMC1.   
For compound dose response studies, assays with similar protocol were 
performed in 384 well plates and imaged using a 20X air objective (NA = 0.45) with 4 
× 4 binning, and large 4 × 4 to 6 × 6 images were taken using an automated stage.  
Images were analyzed using ImageJ software and the macro developed (Supplementary 
Method 2). 
 
3.5.10.  Clustering analysis 
Life stage assay results were compiled into a data frame of continuous variables 
(see Supplemental Table 3).  For each assay, data was scaled about the mean for that 
particular assay.  Scaled data was then used to find the Euclidean distances of each 
compound from other compounds and generate a distance matrix for the entire data 
frame.  The distance matrix was then used to generate a dendrogram using the Ward 
error sum of squares hierarchical clustering method as defined by Ward in 1963 (Ward 
Jr, 1963) and improved upon by Murtagh and Legendre (Murtagh, 2014).   A code was 
developed and run using R studio (Supplementary Method 3).  Label coloring is only 
included for identification purposes, and has no influence on cluster composition in the 





3.5.11.  Mouse model of chronic C. parvum infection 
The animal care guidelines were strictly followed for all animal studies, and 
were performed only after obtaining approval by the University of Vermont 
Institutional Animal Care and Use Committee.   
NOD SCID gamma mice studies were performed as previously described 
(Jumani et al., 2018).  Mice that were 3 weeks (± 3 days) of age were purchased from 
Jackson Laboratories, allowed to acclimatize for one week, and then infected with 
100000 oocysts per mouse.  Oocyst shedding in feces was monitored by qPCR for 18s 
rRNA.  DNA was extracted by the Omega bio-tek’s E.Z.N.A. stool DNA kit per the 
manufacturer’s protocol, with a modification of initialy using 6 flash freeze and thaw 
cycles in liquid nitrogen to disrupt oocysts.  Different amounts of oocysts were spiked 
in feces, followed by DNA extraction and qPCR to generate a standard curve, which 
was run each time and used to calculate oocyst shed per mg feces.  Mice consistently 
started shedding detectable oocysts in feces by qPCR 6 days after infection.  Hence, 
mice were treated twice daily with 50 mg/kg of compounds by oral gavage from 7th day 
after infection for 4 days, and oocysts shedding in feces was monitored every day after 
onset of treatment.  Relapse was tested for 7 days after cessation of treatment.  Based 
on power calculations using Statistical Solutions, LCC’s software, 4 mice per group 
were used to obtain at least 50% reduction in parasite infections with a power of 80%. 
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3.6.  Supplementary Methods 
 
3.6.1.  Supplementary Method 1.  ImageJ macro for quantification of DNA 
synthesis assay. 
 
Title = getTitle(); 
Title = replace(Title, ".tif", ""); 




run("Enhance Local Contrast (CLAHE)", "blocksize=9 histogram=256 maximum=3 
mask=*None*"); 
run("Enhance Local Contrast (CLAHE)", "blocksize=9 histogram=256 maximum=3 
mask=*None*"); 




run("Convert to Mask"); 
selectWindow("lectin-"+Title); 




run("Convert to Mask"); 
run("Fill Holes"); 
run("Watershed"); 
run("Analyze Particles...", "size=50-Infinity circularity=0.50-1.00 show=[Count 









run("Analyze Particles...", "size=3-Infinity circularity=0-1.00 show=Outlines display 
clear summarize in_situ"); 
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3.6.2.  Supplementary Method 2.  ImageJ macro for quantification of DMC1 in the 
asexual to sexual conversion assay. 
Title = getTitle(); 
Title = replace(Title, ".tif", ""); 
run("Stack to Images"); 
rename ("nuc-"+Title); 
run("Subtract Background...", "rolling=15"); 
run("Unsharp Mask...", "radius=3 mask=0.70"); 
//run("Threshold..."); 
setAutoThreshold("Huang dark"); 
run("Convert to Mask"); 
run("Watershed"); 


















run("Convert to Mask"); 
run("Fill Holes"); 
run("Watershed"); 
run("Analyze Particles...", "size=2-50 circularity=0.06-1.00 show=[Count Masks] 











run("Analyze Particles...", "size=0-Infinity circularity=0.5-1.00 show=Outlines display 
clear summarize in_situ"); 





3.6.3.  Supplementary Method 3.  Code used for clustering analysis using R studio. 
#For generating Dendrograms 
 
setwd("WORKING DIRECTORY HERE") #working directory 










##### Data Import ###### 
 
comp_df<-data.frame(read.xlsx("FILE NAME.xlsx",  
                              sheetName = "SHEET NAME", header = TRUE, rowIndex = 




names(comp_df)<-c("Name","Lab Code", "Mechanism", "ID", "Invasion", "DNAsyn", 
"Motility", "SexDiff") 
 
##### Data Cleaning ######  
 
 
##Preparing Data for Dendrograms  
 
char_list<-vector(mode = "integer", length = 33)  #Empty vector to hold count values 
letter_list<-c("A","B","C","D","E","F","G","H","I","J","K", 
               "L","M","N","O","P","Q","R","S","T","U","V", 
               "W", "X", "Y", "Z", "AA", "AB", "AC", "AD",  
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               "AE", "AF", "AG") #Possible Groups, this needs additions if more groups 
emerge 
for(x in comp_df[,3]){  #Counting group ID occurances 
  char_list[which(x == letter_list)] <- char_list[which(x == letter_list)] + 1 
} 
 
repeated_values<- letter_list[which(char_list > 1)] #List of repeated groups 
 
i<-1 
for(y in comp_df[,3]){  #IDs compounds belonging to a group 
   
  if (y %in% repeated_values){ 
    comp_df[i,9]<-which(as.character(repeated_values) == as.character(y)) 
  }else{ 
    comp_df[i,9]<-0 
  } 
  i <- i + 1 
} 
 
### Graphs Generation ###  
 
labelColors = c("#0000FF", "#FF3030", "#228B22", "#D15FEE", "#00CED1", 
"#8B7355", "#E67732", "#AD00FA", "#FEFF0E" ) #blue, red, green, orchid, turquoise, 
brown, purple, bright yellow 
 
colLab <<- function(n) {      #Function for coloring labels and assigning compund 
names as labels 
  if(is.leaf(n)) { 
    a <- attributes(n) 
    attr(n, "nodePar") <-c(a$nodePar, list(lab.col = labelColors[which(repeated_values 
== as.character(comp_df[a$label,3]))], lab.font = 2)) 
    attr(n, "label") <- as.character(comp_df[a$label,1]) 
  } 
  n 
} 
 
cluster_counts<- c(2,3,4,5,6,7) #Number of Clusters 
 
clust_df=dist(comp_df[,c(5:8)], method = "euclidean") #distance matrix with euclidean 
values 
 
dendro_df<-hclust(clust_df,method = "ward.D2")%>% as.dendrogram() 
 




comp_mean<-apply(na.omit(comp_df[5:8]), 2, mean) 
comp_sd<-apply(na.omit(comp_df[5:8]), 2, sd) 
comp_max<-apply(na.omit(comp_df[5:8]), 2, max) 
comp_min<-apply(na.omit(comp_df[5:8]), 2, min) 
comp_mad<-apply(na.omit(comp_df[5:8]), 2, mad) 
 





clust_scaled_dist<-dist(comp_df_scaled, method = "euclidean") 
 




##### Dendrograms ############ 
 
par(mar = c(8, 4, 5, 17))  #margins 
 
plot(dendrapply(dendro_scaled_dist, colLab), horiz = TRUE,  
     main = "Using Numerical Data Scaled about the mean\n Euclidean Distances 
\nWard Method\nEgress Ratio",  
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3.8.  Figure Legends 
Figure 1.  Transmission electron microscopy timecourse showing C. parvum life 
cycle stages present in the HCT-8 cell culture system.  C. parvum Iowa oocysts 
purified from calf feces were artificially excysted in vitro and used to infect HCT-8 
monolayer.   Parasite was allowed to grow and at different time points from 12 h to 96 
h post-infection, cells were analyzed by transmission electron microscopy (TEM) to 
visualize different stages of the parasite life cycle observed in our culture system. 
 
Figure 2.  Invasion Assay.  (A) Demonstration of the parasite stage investigated during 
the invasion assay using representative TEM images of C. parvum Iowa oocysts and 
infected HCT-8 cells (Scale = 500 nm for oocysts image and 2 µm for image with 
infected cell).  (B) Schematic of experimental design.  Confluent HCT-8 monolayers 
were treated with 2 × EC90 of compounds for 1 h followed by infection with oocysts 
triggered for excystation.  Oocysts were allowed to excyst to release sporozoites for 
invasion of HCT-8 cells to form parasitophorous vacuoles for 3 h in presence of EC90 
concentration of compounds, following which cells were washed, fixed, stained, 
imaged and counted.  (C) Representative images of invaded parasites stained with Vicia 
villosa lectin (green) and host cell nuclei (blue) after treatment with DMSO control or 
EC90 concentration (11.34 µM) of wiskostatin.  Scale = 10 µm.  (D)  Quantified results 
for various controls and compounds identifying 2,4-diaminoquinazoline series from 
MMV Malaria Box to be potent inhibitors of invasion.  Each point represents the mean 




Figure 3.  DNA Synthesis Assay.  (A) TEM images of C. parvum infected HCT-8 
cells demonstrating parasite processes measured by the DNA synthesis assay (Scale = 
500 nm).  (B) Overview of the experimental methodology.  Confluent HCT-8 cell in 
glass bottom plates were infected with C. parvum, and following invasion compounds 
were added at EC90 concentration.  At 9 h post-infection, 10 µM EdU was added for 
another 2 h and then cells were washed, fixed, stained and imaged.  (C)  Representative 
40X air images of parasitophorous vacuoles (green), nuclei (blue) and EdU (magenta) 
after treatment with DMSO, EC90 concentration (1.33 µM) of quinolinol A-6, or 10 
mM hydroxyurea.  Scale = 5 µm.  (D)  EdU incorporation was quantified demonstrating 
quinolinols and allopurinol-based series effect process that lead to inhibition of DNA 
synthesis.  Data are mean and SD of at least 2 independent experiments, except for 
paromomycin, 2,4-diaminoquinazolines and D-44 wherein data represents mean from 
one experiment.  ND represents data not determined. 
 
Figure 4.  Assay to measure parasitophorous vacuole (PV) egress, merozoite 
motility and reinvasion to form new parasitophorous vacuole.  (A)  Live 
microscopy DIC images taken using 60X oil objective displaying rapid events of 
parasitophorous vacuole (PV) egress to release motile merozoites that re-invade 
neighboring HCT-8 cells to form a new infection.  Scale = 5 µm.  (B)  Live microscopy 
40X air DIC timecourse images of C. parvum parasitophorous vacuoles in presence of 
allopurinol-based C-1 scaffold at 2 × EC90 concentration (1.3 µM) or matched DMSO 
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control.  Scale = 10 µm.  (C)  Timecourse infection experiment in the presence of 
DMSO or allopurinol-based scaffold C-1 at EC90 or 2 × EC90 concentration measuring 
parasitophorous vacuole numbers over time by immunofluorescence microscopy.  Data 
points are mean and SD, n=4, representative of 3 independent experiments.  (D)  
Outline of the experimental design.  Infected HCT-8 cells were treated with EC90 
concentration of compound 3 h after infection and parasitophorous vacuole numbers 
counted before egress at 6 h (count 1), and after egress at 19.5 h after infection (count 
2) by immunofluorescence microscopy and ImageJ macro.  Parasitophorous vacuole 
ratio of count 2 by count 1 taken for all compounds as a read out for the assay.  (E)  
Quantification of ratio of parasitophorous vacuole numbers showing all compounds 
inhibited parasite numbers compared to DMSO, but to varying degrees with good 
correlation observed within chemical series.  Data combined from at least 2 
independent experiments with 4 technical replicates each, mean and SD shown.  
 
Figure 5.  DMC1 (cgd_1690) mRNA and protein expression correlates with 
appearance of sexual stages.  Confluent HCT-8 cells grown in 12 well plates were 
infected with excysted C. parvum oocysts for different amounts of time before 
harvesting cells for (A) isolation of RNA followed by quantitative reverse transcription 
PCR (qRT-PCR) to quantify expression of C. parvum DMC1 (cgd7_1690) relative to 
18s RNA, and (B) transmission electron microscopy (TEM) to visualize stages of 
parasitic vacuoles at given times.  To get a more specific time-frame correlation, both 
(A) and (B) were analyzed from the same experiment, and the data are representative of 
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2 independent experiments.  Scale bar = 500nm.  Mouse monoclonal antibodies were 
raised against recombinant C. parvum DMC1 and used for immunofluorescence 
staining in in (C) and (D).  (B) and (C) Infected HCT-8 monolayers were harvested at 
different time points, fixed and stained for total parasitic vacuoles with Vicia villosa 
lectin (green), for nuclei with Hoechst (blue), and DMC1 (red).   (B) Higher resolution 
images taken with a 60X oil immersion objective showing representative vacuoles with 
DMC1 (red) expression absent in multi-nucleate parasitic vacuoles at 72 h post-
infection.  Scale bar = 5 µm.  (C) Large 2 × 2 images were taken using a 40X air 
objective as described in materials and methods for counting total and DMC1 positive 
parasitic vacuoles.  Data combined from 2 biological experiments with at least 127 
(except 14 h, where n=92) lectin positive vacuoles per experiment were considered for 
counting DMC1 positive parasites per time point. 
 
Figure 6.  Assay to Measure Asexual to Sexual Stage Conversion.  (A)  Schematic 
demonstrating experimental overview for compound dose response studies against 
asexual to sexual stage conversion as measured by DMC1.  HCT-8 cells were infected 
for 48 h, followed by addition of compound for another 24 h.  Cells were then washed, 
fixed, stained, imaged and parasites counted.  (B) Dose repose curves against the 
asexual stage as measured by the regular 48 h infection assay using V. villosa lectin, 
compared with DMC1 inhibition in the asexual to sexual stage conversion assay for 
piperazine, D-1 and 2,4-diaminoquinazoline, B-1.  The mean and SD from at least 2 




Figure 7.  Clustering Analysis of Life Stage Assay Results for 55 Anti-
Cryptosporidium hits.  Results from the life stage assays were used to calculate a 
distance matrix using Euclidean distances followed by clustering to generate a 
dendorgram using the Ward error sum of squares hierarchical clustering method as 
described in the methods section.  Compound classes are shown in colors, whereas 
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Supplementary Table 1.  Compounds from the Medicine for Malaria Venture 




































































































































Supplementary Table 2.  Grouping of select inhibitors based on the asexual life 
stage assays. 
 





B-1 yes no 1.58
B-5 yes no 1.49
B-13 yes no 1.42
B-23 yes no 1.55
A-2 no yes 0.69
A-5 no yes 0.32
A-6 no yes 0.79
Floxuridine no no 0.74








Supplementary Table 3.  Compiled in vitro life stage assays, parasite persistence 































Nitazoxanide 13.83 -9.16 1.40 73.48 static no
Gentian Violet -6.62 47.40 1.37 8.16 exponential no
Pyrvinium 25.69 88.30 0.61 68.07 static no
2,4-diaminoquinazoline_B-13 B-13 2,4-diaminoquinazoline 82.51 -3.46 1.42 11.26 exponential no
AN11429 -2.64 25.22 1.57 -51.37 exponential yes
Torkinib -21.41 -16.16 1.61 11.19 linear no
2,4-diaminoquinazoline_B-23 B-23 2,4-diaminoquinazoline 83.80 1.59 1.55 -6.40 static
Tegaserod 13.93 -6.72 1.01 12.05 linear no
Allopurinol-based_C-1 C-1 Allopurinol-based -10.80 91.44 0.80 30.35 exponential no
AN6426_LeuRS inhibitor tRNA Synthetase inhibitor -16.44 86.81 0.93 62.47 no
DDD01510706_Lysyl-tRNA tRNA Synthetase inhibitor -7.33 85.17 0.83 75.98 exponential yes
ATG8-inhibitor_MMV001246 ATG-8 inhibitor -7.41 72.11 0.43 45.66 exponential no
Floxuridine Pyrimidine analog -28.03 20.42 0.74 -7.53 linear no
Piperazine_D-1 (MMV665917) D-1 Piperazine -25.16 23.98 1.86 79.37 exponential yes yes
AN8453 -19.64 5.29 1.42 2.66 no
BK1-1294 -6.64 -5.73 1.49 45.56 no
DDD01510289_Lysyl-tRNA tRNA Synthetase inhibitor 7.92 86.82 0.90 75.58 exponential yes
BRD7929_Phe-tRNA tRNA Synthetase inhibitor 0.40 93.39 0.72 63.11 exponential yes yes
Cladosporin_Lysyl-tRNA tRNA Synthetase inhibitor -6.64 93.15 0.68 94.16 exponential
Piperazine_D-28 D-28 Piperazine -13.23 3.38 1.28 81.40 exponential yes yes
Clofazimine 66.45 88.58 0.77 89.18 linear no
ATG8-inhibitor_MMV665909 ATG-8 inhibitor -12.01 90.80 0.41 53.05 exponential no
Quinolinol_A-6 A-6 Quinolinol -20.21 89.49 0.79 17.22 exponential
Itraconazole -29.72 -4.89 1.77 63.93 linear no
Atorvastatin HMG-CoA reductase inhibitor -38.43 -4.60 1.88 36.34 linear no
Piperazine_D-44 D-44 Piperazine -11.48 12.07 2.21 74.35
Quinolinol_A-5 A-5 Quinolinol -13.46 99.95 0.32 65.35 no
AN7973 -21.37 23.10 1.70 -52.26 exponential yes
UW2093_Met-tRNA tRNA Synthetase inhibitor -9.92 83.14 1.99 7.79 exponential yes
2,4-diaminoquinazoline_B-1 B-1 2,4-diaminoquinazoline 56.43 -31.43 1.58 14.70 linear no
Wiskostatin (MMV672987) N-WASP inhibitor 88.58 36.39 1.04 45.76 exponential no
Quinolinol_A-2 A-2 Quinolinol -15.19 100.00 0.69 36.33 no
AN12387 -12.29 31.06 1.21 58.22 yes
Paromomycin -28.42 18.81 2.15 43.80 linear yes no
2,4-diaminoquinazoline_B-5 B-5 2,4-diaminoquinazoline 82.99 -9.25 1.49 7.84 static no
DDD01538714_Lysyl-tRNA tRNA Synthetase inhibitor 14.15 89.96 0.95 86.44 exponential yes
Cal44 9.83 -18.41 2.16 -5.22 linear
Halofuginone_Propyl-tRNA tRNA Synthetase inhibitor 6.92 88.20 0.69 51.29
Oryzalin Plant Microtubule agent 1.23 12.01 2.39 -62.75
Cal49 -5.39 -27.43 1.51 -4.71 linear
Allopurinol-based_C-4 C-4 Allopurinol-based 9.11 99.18 0.48 41.59 exponential no
Docetaxel Human Microtubule agent -8.63 16.66 1.76 34.13
Cal48 -22.39 -45.18 1.63 50.94
Cal46 -0.21 -17.33 1.72 21.47 linear yes no
Allopurinol-based_C-5 C-5 Allopurinol-based 13.07 98.17 0.31 30.15 exponential no
DDD01538844_Lysyl-tRNA tRNA Synthetase inhibitor 4.99 81.67 0.89 94.82 exponential yes yes
BK1-1553 CDPK1 inhibitor -3.92 9.91 1.94 -13.81 yes no
Cal50 -27.90 -25.65 1.44 49.26 exponential no
Allopurinol-based_C-2 C-2 Allopurinol-based 3.65 98.27 0.34 13.19 exponential no
Cal45 -18.17 -16.81 1.35 1.98 exponential
Nilotinib -21.88 22.05 1.05 70.96 static no
Cal47 -10.53 -61.28 1.44 -36.14 linear yes no
BK1-1770 CDPK1 inhibitor -2.21 4.28 1.44 -37.39
BK1-1369 CDPK1 inhibitor -7.94 16.97 1.41 -4.30 yes no
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CHAPTER 4: DISCUSSION AND FUTURE DIRECTIONS 
This chapter will briefly summarize the results from chapters 2 and 3, provide 
an update on developments that have occurred most recently in this rapidly changing 
field, and then discuss strategies for further development of MMV665917 and 
additional needs to establish a Cryptosporidium drug development pipeline. 
We have identified a highly promising piperazine-based lead, MMV665917 
from the Medicines for Malaria Venture Open Access Malaria Box that was active 
against C. hominis and C. parvum Iowa strain and field isolates in vitro, was efficacious 
in the acute interferon-γ (IFN-γ) mouse model, as well as appeared to cure the chronic 
NOD SCID gamma (NSG) mouse model of cryptosporidiosis (Chapter 2).  On the other 
hand, paromomycin and clofazimine were effective in the IFN-γ mouse model, but did 
not cure the disease in NSG mice.  Since the NSG mice are highly 
immunocompromised, we hypothesized that the compounds need to be cidal to cure the 
disease in the NSG mouse model.  To aid general in vivo efficacy studies, we 
developed an in vitro pharmacodynamic (PD) parasite persistence assay to determine 
potentially static versus cidal compounds and identify the concentration of compound 
required to maximize the rate of parasite elimination (Chapter 2).  MMV665917 
appeared cidal in the parasite persistence assay, whereas, nitazoxanide, paromomycin 
and clofazimine seemed potentially static (Jumani et al., 2018). 
Currently, there are several large phenotypic screening efforts underway to 
identify anti-Cryptosporidium compounds, with thousands of hits expected soon 
(Bessoff, Sateriale, Lee, & Huston, 2013; Bessoff et al., 2014; Chao et al., 2018; Love 
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et al., 2017).  In the absence of a reliable drug, the in vitro and in vivo characteristics 
desired for prioritization are not known.  A strategy to obtain diverse hits with different 
mechanisms of action has been used to prioritize hits for parasitic drug development 
(Burrows et al., 2017; Burrows, van Huijsduijnen, Mohrle, Oeuvray, & Wells, 2013; 
Katsuno et al., 2015).  With a goal to obtain diversity among anti-Cryptosporidium hits, 
we developed a range of life-stage specific assays and screened a set of 34 “learner” 
hits that had activity against the asexual stage of C. parvum.  Interestingly, several 
compounds behaved differently in the life-stage assays, forming distinct groups, but 
structural variants and multiple different tRNA synthetase inhibitors grouped together 
(Chapter 3).  
Anti-Cryptosporidium drug development efforts have been growing at an 
extremely fast pace and large developments have been made since the start of this 
thesis.  In fact, significant updates have occurred in the past few months during the 
writing of this thesis.  MMV665917 has been shown to be highly efficacious in the 
clinical calf model, reducing parasite shedding as well as alleviating the symptoms of 
diarrhea (Stebbins et al., 2018).  The compound also abrogated parasite shedding in 
gnotobiotic piglets infected with the C. hominis TU502 strain, but surprisingly, the 
compound alone induced diarrhea in this model, unlike in calves wherein it reduced C. 
parvum induced diarrhea (personal communication with Dr. Saul Tzipori, Tufts 
University).  Interestingly, MMV665917 has shown the best anti-C. hominis efficacy to 
date in the gnotobiotic piglet model of cryptosporidiosis.  The most potent variant of 
MMV665917 identified, D-28, also cured cryptosporidiosis in the NSG mouse model.  
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After a four-day treatment with twice-daily dose of 60 mg/kg of MMV665917 or D-28 
variant, mice did not shed any detectable parasites in feces for up to 26 days after 
cessation of treatment (Huston lab, unpublished data). Since MMV665917 is active 
against P. falciparum blood stages and these cultures can be continuously maintained in 
vitro, resistance studies were performed in this system.  More than 20 different 
MMV665917 resistant strains with varying degrees of resistance with a 1.3 to > 36 fold 
decrease in potency have been obtained (personal communication with Dr. Audrey R. 
Odom, Washington University School of Medicine).  These resistant strains can be 
sequenced and can potentially provide the likely target of the drug.  Large-scale 
screening has been performed using DMC1 as a marker to identify asexual and sexual 
stage specific and pan stage inhibitors (Huston lab, unpublished data).  Genetic strains 
of Cryptosporidium with the inosine-5′-monophosphate dehydrogenase (IMPDH) 
knockout have been created and were viable in vivo, ending the IMPDH drug 
development program (Dr. Boris Striepen’s talk at Bill and Melinda Gates Foundation’s 
2nd Annual Cryptosporidium Drug Discovery Program Meeting, Tres Cantos, Spain, 
June 2017).  The IMPDH inhibitors had been earlier identified using target-based 
screens and were shown to be active in the acute IL-12 knockout mouse model of 
cryptosporidiosis (Gorla et al., 2012; Gorla et al., 2014).  
 
4.1.  MMV665917 Lead Optimization and Pharmacokinetic Considerations 
MMV665917 is a promising lead compound with impressive activity in several 
animal models, something which has not been seen with any other anti-
Cryptosporidium compound to date.  The compound is quite safe in vitro, except for 
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potential hERG liabilities at higher concentrations and drug-drug interaction issues, 
which are compounded by a modest anti-Cryptosporidium in vitro potency.  The other 
initial concern is the compound-induced diarrhea in gnotobiotic piglets during initial 
studies.  Since the compound was highly efficacious, a more comprehensive dose-
response study with a lower dose needs to be tested to abrogate compound induced 
diarrhea.  Preliminary structure-activity relationship (SAR) studies appear promising, 
lending credence to addressing these issues using a medicinal chemistry program.  The 
success of the medicinal chemistry program would depend on understanding the 
pharmacokinetic parameters (PK) of MMV665917 that drive in vivo efficacy.  The first 
step would be to perform a thorough PK study with 30 and 60 mg/kg of MMV665917 
in mice and model these data to design further in vivo experiments to determine 
minimal dose(s) required to achieve efficacy.  A comparison of the PK parameters of 
the variant, D-28, with those of the parent could provide helpful insights about PK 
parameters that drive in vivo efficacy.  A comprehensive medicinal chemistry program 
can not only aid in identifying compounds with improved potency, but also variants 
with different PK properties, which can then be used as tools to understand PK 
properties that drive in vivo efficacy. 
The ideal PK parameters for anti-Cryptosporidium drugs have been a major 
unanswered question in Cryptosporidium drug development in general.  There have 
been reports with Bumped Kinase inhibitors (BKI) and IMPDH inhibitors suggesting 
that intestinal exposure is important for efficacy (Arnold et al., 2017; Gorla et al., 
2014).  Using structural variants of BRD7929 (a validated Cryptosporidium Phe-tRNA 
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synthetase inhibitor (Kato et al., 2016)) with different PK properties, it is clear that 
systemic exposure is critical for activity of this series in the NSG mouse model.  Hence, 
we believe the optimal PK parameters could vary depending on the compound class.  
Added on, there is a possibility that the PK parameters could depend on the mouse 
model used as well, as different mouse models have been used in the above studies.  As 
in immunocompromised patients, the biliary tree gets infected in the NSG mice (data 
not shown) and it is possible that this site acts as a reservoir of infection, with systemic 
or enterohepatic recirculation of drugs required to cure the disease from these animals.  
Paromomycin is a poorly absorbed drug that reduces oocyst shedding in the NSG mice, 
but the infection relapses on cessation of treatment (Jumani et al., 2018).  
Paromomycin’s inability to cure the biliary tree infection in these mice could be one 
among several reasons why paromomycin-treated mice relapse.  To address variability 
between mouse models of infection, we have tested the BKI and IMPDH inhibitors in 
the NSG mouse model, but they were ineffective.  The results are inconclusive, as the 
inactivity could be due to several reasons apart from PK parameters.  Interestingly, 
clofazimine was active in the IFN-γ mouse model but not in the NSG model, whereas, 
MMV665917 was active in both models.  Thus, an understanding of MMV665917 PK 
parameters would shed some light on understanding if the PK parameters desired for 
various mouse models are different.  Confidence in these studies can be added by 
comparing several leads across the different mouse models of cryptosporidiosis. 
An in vitro transmembrane assay could be potentially used to predict the PK 
properties desired (see Appendix II).  This would involve developing a polarized 
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monolayer of intestinal cells using a transmembrane chamber and testing efficacy of 
compounds when added to the apical or basolateral side of the polarized monolayer.  
This assumes the apical side represents the intestinal lumen, while the basolateral side 
represents systemic exposure.  The major challenge for the assay is to measure and 
correct for transport of compounds across the polarized monolayer. 
 
4.2.  Target of MMV665917 
A knowledge of the target of MM665917 is not mandatory for drug 
development but would have several advantages.  A knowledge of the target would be 
extremely helpful in the medicinal chemistry program and would help in increasing 
selectivity for the parasite over the unwanted host toxicity.  There is a possibility that 
MMV665917 might fail as a drug candidate due to PK, selectivity issues, cost, or other 
reasons, but the target can potentially be a validated drugable candidate, especially as 
MMV665917 works remarkably well in several animal models.  Thus, identification of 
the target would be an invaluable resource that can be helpful in developing new 
classes of compounds against cryptosporidiosis using a target-based screening strategy. 
Since MMV665917 was identified from a whole cell screening assay where the 
parasite growth is dependent on the host, the target of the drug could be in the parasite 
or host cell pathway that is essential for parasitic growth.  Since the drug is active 
against the related Apicomplexan parasite Plasmodium blood stages as well, we 
hypothesize that the drug potentially targets the parasite and not the host and that the 
target is conserved between the 2 parasites.  The resistant P. falciparum strains recently 
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generated serve as a promising tool to identify a target.  We are also collaborating with 
GlaxoSmithKline (GSK) to use their thermal proteome shift technology to identify a 
potential proteome target (Savitski et al., 2014).  One of the partially active variants, D-
74, is closely related to a kinase inhibitor identified in a patent application which was 
found using the chemical structure search function of the Chemical Abstracts Service 
(CAS) SciFinder database (https://scifinder.cas.org/).  Using a similar strategy, our 
collaborator Dr. Marv Meyers found C. parvum Cyclin Dependent Kinase 8 to be a 
potential target for MMV665917 and is using medicinal chemistry strategies to test the 
same.  Our collaborator Dr. Ray Hui at the University of Toronto has expressed several 
C. parvum kinases and is currently screening MMV665917 and its select variants 
against the kinases.  These different strategies could yield a potential target, which can 
be confirmed in C. parvum by performing over-expression and mutation studies using 
the recently developed CRISPR/Cas9 genetics system (Pawlowic, Vinayak, Sateriale, 
Brooks, & Striepen, 2017; Vinayak et al., 2015). 
 
4.3.  Compare Mouse Models and in vitro Assays 
Numerous mouse models and in vitro assays are currently in use for 
Cryptosporidium drug development (Castellanos-Gonzalez et al., 2013; Gorla et al., 
2014; Jumani et al., 2018; Love et al., 2017; Manjunatha et al., 2017; Ndao et al., 
2013).  The in vitro and in vivo data reported in this thesis are the first direct 
comparison of a large number of promising anti-Cryptosporidium hits and leads from 
various groups in the same in vitro assays and in vivo mouse model (Bessoff et al., 
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2013; Bessoff et al., 2014; Castellanos-Gonzalez et al., 2013; Downey, Chong, 
Graczyk, & Sullivan, 2008; Gorla et al., 2012; Jumani et al., 2018; Kato et al., 2016; 
Love et al., 2017; Shibata et al., 2011).  This has been extremely helpful in directly 
comparing compounds and characterizing them.  It is interesting to note that many of 
the compounds that were active in the acute mouse models were not active in the NSG 
mouse model of cryptosporidiosis.  This includes the IMPDH inhibitors whose target 
has been shown to be non-essential for Cryptosporidium.  The failure of IMPDH 
inhibitors serve as a classical example for drawbacks of target-based drug development 
for poorly studied neglected disease where target validation is extremely difficult.  This 
also raises questions about the validity of the acute IL-12 knockout mouse model for 
Cryptosporidium drug development.  BKI-1294 was also inactive in NSG mice, but has 
shown efficacy in the clinical calf model when given prophylactically.  It is interesting 
to note that MMV665917 and AN7973 had activity in the NSG mice, and when dosed 
after onset of infection in calves worked much better than prophylactic administration 
of BKI-1294 (Huston lab, unpublished data).  These preliminary correlations are 
interesting to note, but too small in number to draw any significant conclusions.  The 
only other compound (apart from MMV665917 and AN7979) tested with good activity 
in the calf model is a phosphatidylinositol-4-OH kinase (PI(4)K) inhibitor, KDU731, 
from Novartis (Manjunatha et al., 2017).  This compound is the only other promising 
lead that has not been tested in our in vitro assay or NSG mouse model.  A variant of 
the KDU731 is on course to be tested in these models for a direct comparison and could 
yield meaningful results.  KDU731 was tested in the chronic IFN-γ mouse model using 
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a mouse adapted nano-luciferase (Nluc) expressing C. parvum (Manjunatha et al., 
2017).  The lysine-tRNA synthetase inhibitors from Dundee have been tested in this 
chronic IFN-γ mouse model as well as the NSG mouse model with good efficacy 
correlation between the two mouse models.  Hence, we expect the KDU731 to have 
similar activity in our NSG mouse model as well. 
With many compounds inactive in the NSG mice but active in the other acute 
mouse models, there was a growing concern in the drug development community that 
the bar is very high to achieve activity in the NSG mice, which might eliminate most of 
the hits.  This has not been the case, as after testing 29 different scaffolds in the NSG 
mice, we have found 9 different scaffolds (~31% hit rate) with activity in the NSG 
mouse model.  There is a chance that screening in the NSG mouse model alone might 
eliminate interesting hits.  Since there is no gold standard drug, the only way to know 
that activity in mouse models correlates with clinical efficacy is by identifying a drug 
that works in humans.  For now, it could be extremely valuable to test all the existing 
promising leads in the critical mouse models and compare efficacy with the  clinical 
calf model.  This would be invaluable in establishing a standardized drug development 
cascade and reducing variability and redundant efforts for future lead identification 
studies.  Further value can be added to these comparisons by understanding correlations 
between in vivo efficacy in various mouse models and efficacy in the parasite 
persistence assay. 
Similarly, there are several different in vitro assays used to identify hits, which 
include immunofluorescence assays, assays using Nluc expressing parasites, RNA 
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detection using real-time quantitative PCR assay, and assays measuring host cytopathic 
effect (Bessoff et al., 2013; Castellanos-Gonzalez et al., 2013; Chao et al., 2018; Love 
et al., 2017; Vinayak et al., 2015).  A correlation between assays using a learner set of 
compounds needs to be established to directly compare hits from the various assays.  
The assays also use different sources of oocysts, with the C. parvum Iowa strain from 
Bunch Grass Farm and the University of Arizona Sterling Laboratory being the major 
sources.  There have been studies from our group and others to compare activity of 
promising hits against the Iowa strains and field isolates of C. parvum, and C. hominis 
TU502 strain as well.  This should be a requirement for Cryptosporidium drug 
development, and studies against C. hominis field strains should also be performed, 
given the variation in virulence across strains.  The latter studies are usually hindered 
due to lack of availability. 
 
4.4.  Prioritization Assays 
The life stage assays have been used in this thesis to determine diversity based 
on predominant effect on compounds on the life stages.  There is a possibility that the 
compounds grouped in the same cluster by this method could have different 
mechanisms of action, i.e., compounds could be affecting different pathways that 
provide the same life stage affect.  This method has a caveat that it could potentially 
eliminate useful drug candidates at an early stage.  However, the current prioritization 
method is random and this provides a logical method that has worked well for other 
neglected tropical diseases (NTDs).  Based on experience with other NTDs, the lack of 
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prioritization has led to numerous cases wherein chemical series were pursued far too 
long, wasting precious resources, time and careers that could have been spent much 
more wisely.  Since there are now an ample supply of early-stage Cryptosporidium 
inhibitors, the risk associated with a high attrition rate in drug development outweighs 
the initial risks of losing a few potential drug candidates. 
The life cycle stage assays used the effective concentration that inhibited 90% 
of parasites in the regular asexual stage assay (EC90) to determine the predominant 
effect of the compounds.  At this concentration (EC90), activity against no single life 
stage alone correlated with efficacy in vivo.  This method is extremely useful in 
grouping hits for obtaining diversity, but does not mean that the compounds do not 
have any activity in the other stages.  A dose response study against all stages would 
help better understand the effect on specific stages, and this could be more helpful in 
determining correlations between stage activity and in vivo efficacy.  This is even more 
critical for the DMC1 assay as the life cycle of cryptosporidiosis has not been validated.  
It is not clear if targeting the asexual (or sexual) stages alone is sufficient for clearing 
the infection in vivo.  Although MMV665917 had a similar potency against the asexual 
stages and DMC1 in vitro, many of the compounds tested had a shifted dose response 
curve with no compound more potent against the DMC1 stage.  Interestingly, all 
compounds that were active in vivo had > 70% at or below a concentration of 9×EC90 
from asexual stage.  
The results from these assays provide valuable starting point information to 
determine if compounds could be potentially synergistic or antagonistic based on life 
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stage activity.  Checkerboard assays with representative compounds from each group 
can be used to test this idea.  These assays also open up doors to explore the biology of 
the parasite.  
The parasite persistence assay for a number of these hits showed that all 
compounds with in vivo efficacy had an exponential or linear rate of parasite 
elimination.  None of the static compounds were active in the NSG mouse model.  Not 
all of the exponential and linear compounds were active in vivo, which indicates the 
importance of other factors including PK and effects on the microbiome, among others.  
In summary, we report MMV65917 as a highly promising lead, a parasite 
persistence assay to determine in vitro rate of kill and concentration desired to 
maximize rate of parasite elimination that can aid in hit-to-lead prioritization studies 
and in designing in vivo experiments.  We also report a range of in vitro life stage 
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APPENDIX I: UPDATES ON DEVELOPMENT OF MMV006169 AND ITS 
VARIANTS FOR TREATMENT OF CRYPTOSPORIDIOSIS 
 
The screen of the Medicines for Malaria Ventures Open Access Malaria Box 
also identified MMV006169 (B-1) as a promising hit with several potent variants (2,4-
diaminoquinazoline series) (Bessoff et al., 2014) and this chapter will discuss some of 
our efforts towards developing these hits for cryptosporidiosis.  Chemical structure 
search using the SciFinder database (https://scifinder.cas.org/) identified the series to be 
related to DBeQ, which is a reversible inhibitor of the p97 ATPase (Chou et al., 2011).  
The protein p97 belongs to the ATPase associated with diverse cellular activities 
(AAA) family, and is conserved across eukaryotic species.  In fact, retrospectively we 
found that DBeQ was one of the active variants identified from our structural activity 
relationship studies (B-23).  This compound behaved similarly to all other 2,4-
diaminoquinazolines in the various life stage assays tested in chapter 3.  The protein 
p97 is involved in a variety of functions, including shuttling of protein across the 
endoplasmic reticulum (ER) membrane as part of the ER-associated degradation 
pathway (ERAD), and is essential for viability in budding yeast (Giaever et al., 2002) 
and mice (Muller, Deinhardt, Rosewell, Warren, & Shima, 2007).  Interestingly, this 
pathway has been explored for drug targets in malaria as several protozoan pathogens 
contain a minimal ERAD pathway when compared to the mammalian host making 
them more sensitive to drugs targeting this pathway (Harbut et al., 2012).   The yeast 
p97 (called cdc48 or YDL126C) protein sequence from lab strain W303 was obtained 
from the Saccharomyces genome database (https://www.yeastgenome.org/) and a 
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protein BLAST was performed against C. parvum Iowa and C. hominis TU502 
genomes on the CryptoDB website (http://cryptodb.org/).  This identified cgd1_330 in 
C. parvum Iowa and Chro.10043 in C. hominis with 63% identity.   
The protein is vital for yeast survival and temperature sensitive mutants of this 
protein have been used to study its function in yeast (Hsieh & Chen, 2011).  We 
intended to make use of this yeast system to study the C. parvum p97 gene and test the 
hypothesis that B-1 inhibits the C. parvum p97.  The high temperature sensitive cdc-48 
mutant strain (cdc48-3) that cannot grow at 37 °C since the cdc48 is not functional 
along with control W303 strain were a kind gift from Dr, Rey-Huei Chen (Institute of 
Molecular Biology, Academia Sinica, and National Defense Medical Center, Taipei, 
Taiwan).  Growth can be rescued in these strains with expression of wild type cdc48 
using a shuttle vector.  We plan to transfect the yeast cdc48-3 mutants with a plasmid 
expressing the C. parvum p97 gene under a gal promotor, and check if this gene 
complements the function of the yeast cdc48-3 mutant at the high temperatures.  The 
cdc48-3 mutant is in the W303 strain background and the genotype of W303 is as 
follows: 
Genotype: MATa/MATα leu2-3,112 trp1-1 can1-100 ura3-1 ade2-1 his3-11,15 
Dr. Doug Johnson provided us with low expressing shuttle vectors p416 and 
high expression shuttle vector p426 (Mumberg, Muller, & Funk, 1994).  When induced 
with galactose the temperature sensitive mutant (cdc48-3) transformed with vectors 
expressing yeast cdc48 grew normally at 30 °C and the growth was partially rescued 
growth at 37 °C with both p416  (Fig. 1) and p426 vactors (Fig. 2).  Surprisingly, the 
168 
 
cdc48-3 mutants with vectors containing C. parvum p97 in p416 (Fig. 1) and p426 
vectors (Fig. 2) did not grow at 30 °C and 37 °C in the presence of galactose.  All these 
strains grew fine in the absence of galactose indicating inhibition of yeast growth upon 
expression of C. parvum p97. 
We also collaborated with Dr. Adam Sateriale in Dr. Boris Striepen’s lab to 
transiently overexpress C. parvum p97 in vitro and check for decrease in MMV006169 
potency.  However, the overexpression did not decrease MMV006169 potency.  The 
transient system is not an ideal system due to low transfection efficiencies combined 
with short window of parasite culture.  It is rather recommended to perform stable 
overexpression, but is more cumbersome as it involves surgeries and passage in mice to 
select the population desired.  We have also collaborated with Dr. Bart Staker to 
express this protein as its ATPase activity can be tested in vitro to determine direct 
inhibition by the compound. 
We also tested three scaffolds from this series, namely B-1, B-5 and B-13 in our 
chronic NOD SCID gamma mouse model of cryptosporidiosis, but the compounds did 
not have any efficacy (data not shown). 
Transmission electron microscopy to visualize parasites after compound 
addition in the parasite persistence assay did not reveal any obvious differences in the 
parasitophorous vacuoles between MMV0061619 and DMSO treated samples (data not 
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 APPENDIX II: UPDATES ON DEVELOPMENT OF MMV403679 AND ITS 
VARIANTS FOR TREATMENT OF CRYPTOSPORIDIOSIS 
 
MMV40679 (C-1) is an allopurinol-based scaffold identified as a promising hit 
from the Medicines for Malaria Venture Open Access Malaria Box (Bessoff et al., 
2014).  This section is going to outlay the developments made towards progressing this 
series for cryptosporidiosis.   There were several promising variants with nanomolar 
potency against C. parvum identified  ((Bessoff, Sateriale, Lee, & Huston, 2013) and 
data not shown).  The washout experiment determined it to be a fast acting drug 
(Bessoff et al., 2013).  It also displayed an exponential rate of parasite decay in the 
parasite persistence assay with maximum rate of parasite elimination achieved at 
3×EC90.  Morphology of parasites were also visualized using transmission electron 
microscopy (TEM) using the parasite persistence assay experimental design (Fig. 1).  
TEM images showed that a higher proportion of parasites were in the meront stage 
compared to DMSO control.  Furthermore, C-1 treated vacuoles were degenerating 
(Fig. 1).  These data indicate that C-1 is cidal and possibly inhibits parasite egress when 
added at 24 hours on a mixed culture.  However, the DNA synthesis assay showed that 
C-1 inhibits DNA synthesis when added earlier in infection cycle (3 hours post-
infection), and hence, was active in the egress, motility and re-invasion assay (Chapter 
3, Fig. 3).  This was not known when the below mouse experiments were being 
conducted and it was assumed that C-1 is an egress inhibitor. 
We tested several variants of C-1 in our chronic NOD SCID gamma mouse 
model of cryptosporidiosis and measured plasma levels of the compounds in these 
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experiments with a view to understand the pharmacokinetic (PK) properties that drive 
in vivo efficacy for this series.  All the variants got absorbed to different degrees with 
20 to 2830 × EC90 plasma levels achieved within 4 hours of a single oral dose of 100 
mg/kg (Fig. 2).  Nevertheless, none of the compounds reduced parasite shedding even 
after 7 days of dosing 100 mg/kg once daily (Fig. 3).  Similar results were found when 
twice-daily dose, each of 50 mg/kg was given to mice for 4 days (data not shown).  
None of the compounds showed any signs of in vitro toxicity against host HCT-8 cells 
up to 100 µM (data not shown).   Surprisingly, C-2 (F5091-0186) was toxic to mice at 
once daily dose of 100 mg/kg and killed mice 3 out of the 4 mice about 7 days after 
cessation of treatment.  However, in the second experiment, it did not have any toxicity 
when 50 mg/kg was given twice a day (total of 100 mg/kg per day) for 4 days.  This 
indicates that the compound is toxic when given at a higher single dose of 100 mg/kg or 
when given for a longer duration of 7 days or both.  Based on the results we planned 
follow-up experiments such that each dose is ≤ 50 mg with not more than 100 mg given 
per day and mice not treated for more than 4 days.   
We hypothesized that the C scaffold requires compounds to be continuously 
available in intestinal (apical side of cells) to be effective.  Since C-2 was poorly 
absorbed compared to other variants, we wanted to test if the compound would be 
active when dosed frequently, such that high levels are continuously available in the 
intestine.  Furthermore, to test the effect of drug on egress, we wanted to target the first 
stage of parasite life cycle in vivo; hence, mice were treated the same day after oral 
gavage with C. parvum oocysts (similar to acute mouse models of C. parvum infection 
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experiments wherein mice are treated soon after infection (Gorla et al., 2014)).   In a 
modification of the egress, motility re-invasion assay, C-1 seemed to be ineffective 
when washed out after ~9.5 hours after infection, but appeared to be partially active 
when added ~9.5 hours post-infection as compared to addition at 3 hours post-infection 
(Fig. 4).  Based on this experiment, in vivo dosing regimens were decided (Table 1).   
Based on gut transit times in mice from published literature (Padmanabhan, Grosse, 
Asad, Radda, & Golay, 2013), mice were treated either with 8 doses every 2 hours (to 
mimic complete exposure with compound added 3 hours post-infection in vitro), or 
given 4 doses every 2 hours after infection (mimic the in vitro washout experiment) (4 
doses a.m.), or given 4 doses every 2 hours from ~10 hours post-infection (to mimic in 
vitro compound addition before egress).  The total dose given was the same in all cases, 
that is, 100 mg/kg, which was divided into 4 doses or 8 doses.  Mice were treated only 
on this day 1, and then mice were allowed to incubate as these mice start reliably 
shedding oocysts in the feces only after 6 days post-infection.  Interestingly, all doses 
reduced oocysts shedding, but unfortunately, the mice starting getting sick about 6 days 
after treated.  The mice treated with 4 doses soon after infection (4 doses am) were the 
worst hit and mice died on day 8 post infection.  Mice treated with 4 days from ~10 
hours post-infection did not die but were lethargic, with mice treated with 8 doses the 
least sick.  Hence, although C-2 reduced oocysts shedding in all conditions (Fig. 5), the 
data are inconclusive as the compound could be indirectly altering oocysts shedding as 
it was lethal to mice.  However, the data is indicative of apical exposure requirement 
for this series, and this should be confirmed with a different non-toxic variant and/or 
175 
 
tested with multiple doses on an established infection.  The timing did not seem to 
make a difference (except for toxicity which could be due to higher amounts per dose 
in 4 doses) The increased toxicity might be related to the age of the mice, as these mice 
were treated approximately a week earlier than the previous experiments.   The toxicity 
might be also due to co-infection of mice. 
To test the apical or basolateral exposure requirement, we developed a transwell 
assay using HCT-8 and measurement of transwell resistance (Fig 6).  The differentiated 
Caco2 cells were first tested in this assay, but an acceptable level of infection could not 
be established (data not shown).  Hence, the assay was established with HCT-8 cells, 
which has the advantage of direct comparison with our regular assay and also, the assay 
is quick with only 2-3 days required to establish the resistance.  The resistance of the 
monolayer decreases when the parasites egress and destroy the monolayer.  Therefore, 
the assay cannot be used for compounds that act on stages after egress.  But for C-1, an 
inhibitor of DNA synthesis, this assay is perfect.  The only caution that the transport of 
C-1 across the monolayer is not known and might need to be determined to interpret the 
assay results.  This assay can also be used to identify egress inhibitors.  Furthermore, 
parasites could be stained using immunofluorescence by the regular assay method and 
imaged (data not shown) adding further value to the assay.  
Scifinder search identified C-1 to be related to a human phosphodiesterase 
(PDE) inhibitor (Meng et al., 2012).  A protein BLAST on CryptoDB of human PDE 
(GenBank: AAC39778.1) identified cgd6_500 as a homolog with E value 3e-35 on 
October 26, 2015.   As with p97, Dr. Adam Sateriale transiently overexpressed C. 
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parvum cgd6_500 in vitro and tested C-1, but the potency did not decrease.  The gene 
needs to be stably expressed to confirm the result.  We have also collaborated with Dr. 
Bart Staker at the Center for Infectious Disease Research to express, purify and 
crystalize the Cryptosporidium protein.  Potential future experiments include 
determining the effect of C-1 and its structural variants on phosphodiesterase activity of 
the protein in vitro using purified protein, and co-crystal structures of the protein with 



































































Figure 2.  Plasma levels of MMV665917 variants in C. parvum 
infected NSG mice. 
C-4 
Mean serum  levels 
67µM (1460 x EC90) at 0.5 h 
130µM (2830 x EC90) at 4 h 
C-2 
Mean serum  levels 
2.5µM (60 x EC90) at 0.5 h 
13µM (330 x EC90) at 4 h 
C-35 
Mean serum  levels 
4.8µM (25 x EC90) at 0.5 h 
3.8µM (20 x EC90) at 4 h 
C-5 
Mean serum  levels 
21µM (330 x EC90) at 0.5 h 






Figure 3.  In vivo C. parvum efficacy study of MMV403679 variants on an 




















































Figure 4.  Washout or addition of MMV403679 (C-1) 
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Figure 5.  In vivo efficacy of MMV403679 variant, F5091-0186 (C-2) soon after 
infection of NSG mice. 
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Figure 6.  Transwell assay to measure effect of apical or basolateral exposure of 





Table 1.  Compound C-2 dosing regime soon after infection 
 
8:00 AM 10:00 AM 12:00 PM 2:00 PM 4:00 PM 6:00 PM 8:00 PM 10:00 PM 12:00 AM
 10^5 oocysts
C-2 Compound A + X X X X X X X X
C-2 Compound B + X X X X - - - -
C-2 Compound C + - - - - X X X X
DMSO D + X X X X X X X X
DMSO E + X X X X - - - -
DMSO F + - - - - X X X X
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APPENDIX III: STRATEGIES TO IDENTIFY DRUG COMBINATIONS FOR 
TREATING CRYPTOSPORIDOSIS 
 
Evolution of drug resistance to monotherapy is a major problem for infectious 
disease, particularly malaria.  We anticipate similar problems with cryptosporidiosis in 
the future.  Hence, efforts should be made to identify drug combinations to treat 
cryptosporidiosis.  To this end, we have tested combinations of drug using our regular 
48 hours asexual assay, wherein compounds are added, alone or in combinations at 3 
hours post-infection and parasite number measured 48 hours post-infection.  This 
strategy has not been very successful in identifying synergistic combinations, with 
itraconazole and tegaserod to be the most synergistic combination determined to date 
(Table 1).  Since we have developed specific life stage assays, we wanted to logically 
combine representative compounds from each cluster to identify potentially synergistic 
or antagonistic set of compounds.  But the invasion assay involves addition of 
compound before infection of host monolayer.  Addition of compounds after 3 hours of 
invasion would lose the effect of compounds on this stage.  One strategy would be to 
design the experiments with compounds added before infection.  We tested this 
experimental design using a combination of nitazoxanide (inactive in the invasion 
assay) and clofazimine (invasion inhibitor) with compounds added before infection.  
The compounds were more potent than in this assay with only few lower concentrations 
providing a window to look for combinatorial effect.  There seemed to be some hint of 
antagonism (Table 2).   
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Addition of compounds early might potentially give an advantage for certain 
compounds that act on the early stages, negating the effect of compounds that act later. 
Also, early on the infection is roughly synchronized with only trophozoites available in 
culture.  It would be more relevant to look for combination of compounds on a mixed 
culture.  Hence, we plan to test compound combinations on an established culture, with 
compounds added at about 24 hours post-infection and parasite number readout taken at 
48 and 72 hours post-infection to cover almost all stages of the life cycle.  Furthermore, 
we also have data from the parasite persistence assay, which similarly tests effects of 
compounds on an established infection.  This assay also differentiates compounds to be 
potentially static while others to be potentially cidal.  It would be ingesting to test if 




Table 1.  Checkerboard assay using the regular 48 h assay with compounds added 
3 h post-infection. 
 











0 0.3225 0.645 1.29 2.58 5.16
91
0 2 8 25 30 91 88
-15 -14 21 25 76 87
92
27 -2 44 61 82 94 85
-8 5 40 90 93 86
92
14 70 94 80 89 81 90
82 76 94 85 83 76
% inhibition





Table 2.  Checkerboard assay with compounds added before infection and 
parasite numbers measure 48 h post-infection. 
 











0 0.11 0.22 0.44 0.88 1.76
95
0 48 66 78 87 94 96
43 69 80 90 94 95
95
51 71 86 93 94 96 95
67 76 89 95 95 95
95
79 89 94 95 96 95 95
88 93 95 96 96 95
% inhibition
97 97 98 98 97 96 96
 
 
 
 
